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ABSTRACT
Obesity is a major health problem in the United States and worldwide. It increases the
risk for type-2 diabetes and cardiovascular diseases. A chronic low-grade inflammation
occurring in white adipose tissue (WAT) is causally linked to the development of insulin
resistance (IR), metabolic syndrome and obesity-associated chronic diseases. The aim of this
dissertation research was to elucidate the WAT function in metabolic syndrome using genetic
(overexpression of an adipose pro-inflammatory hormone, angiotensinogen) and nutritional
manipulations/approaches (caloric restriction and omega-3 fatty acids), with specific emphasis
on the role of inflammation.
Previous research indicates that WAT renin-angiotensin system (RAS) is overactivated in
obesity. However, its role in the pathogenesis of IR is hitherto unknown. Using mice
overexpressing angiotensinogen (Agt), the only precursor for the hypertensive hormone
angiotensin (Ang) II, in WAT, we showed that adipose-specific RAS overactivation leads to
systemic IR. This is at least in part due to Ang II, NADPH oxidase and NF-kB-dependent
increases in WAT inflammation.
Caloric restriction is the main dietary intervention to treat obesity-associated metabolic
disorders. While most health agencies recommend a low-fat diet, energy-restricted high-fat diets
(HFR) are also claimed to be effective in this regard. Here, we show that weight loss due to HFR
is accompanied by improvements of IR but only partial resolution of WAT inflammation.
Further, this diet negatively impacted the adipokine profile supporting the current
recommendations for low-fat diets.
Dietary interventions targeted at reducing WAT inflammation have not been explored in
detail. Eicosapentaenoic acid (EPA) is an omega-3 polyunsaturated fatty acid of marine origin
v

with anti-inflammatory properties. We show that EPA is able to both prevent and reverse highfat diet-induced IR and hepatic steatosis via modulation of WAT inflammation.
In conclusion, primary changes occurring in WAT, such as overexpression of Agt, can
lead to WAT inflammation and systemic IR. Moreover, nutritional interventions targeting at
reducing adiposity (caloric restriction) and inflammation (EPA) can both lead to improvements
in systemic IR. Our findings support the current recommendation of low-fat diets for
improvement in metabolic profile and show that dietary modulation of WAT function can be
used to improve metabolic derangements in obesity.
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CHAPTER I
INTRODUCTION AND OVERVIEW
Obesity is a major health problem in the United States and worldwide. Obesity
increases the risk of premature death and several co-morbidities such as Type 2 diabetes,
cardiovascular disease and several forms of cancer. It is also a feature of the metabolic
syndrome which is characterized by abdominal obesity, hypertension, dyslipidemia and
hyperglycemia. Individuals with the metabolic syndrome are at a higher risk of
developing the obesity-associated co-morbidities. Recent evidence has causally linked
obesity and increased adiposity to the pathogenesis of metabolic syndrome.
Adipose tissue is an endocrine organ which secretes numerous bioactive peptides
collectively known as adipokines. Further, obesity is characterized by a chronic lowgrade inflammation and a dysregulation of adipokine secretion in the adipose tissue,
which can lead to insulin resistance and metabolic syndrome. Angiotensin II, generated
from its precursor angiotensinogen, is among the adipokines of interest to us. We have
used a series of genetic and dietary manipulations to study the role of adipose tissue in
the pathogenesis of the metabolic syndrome. First, we used a mouse model which
overexpresses angiotensinogen to dissect the role of adipose tissue renin angiotensin
system overactivation in the pathogenesis of insulin resistance in obesity. Next we used
different dietary approaches to alleviate the adipose tissue inflammation and metabolic
dysfunctions caused by high-fat feeding. In this regard we studied the role of high-fat
reduced energy diets and high-fat diets supplemented with omega-3 fatty acids to study
the dietary modulation of adipose tissue dysfunction in obesity.
1

The findings of this work will help in furthering the understanding of adipose
tissue dysfunction in obesity and help in development of dietary and pharmacological
interventions to prevent and treat obesity-associated co-morbidities.
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CHAPTER II
LITERATURE REVIEW
Obesity and Type-2 diabetes - trends in the United States and the world
Obesity is a major health problem in the Unites States (US) with an estimated
68% of the adult population being overweight or obese [1]. The classification of
overweight and obesity are based on the calculation of body mass index (BMI), which is
defined as weight in kilograms divided by the square of the height in meters. Overweight
is defined as a BMI of 25 to 29.9 kg/m2 and obesity as a BMI of greater than or equal to
30 kg/m2 [2]. According to the National Health and Nutrition Examination Survey
(NHANES) data [1], the prevalence of overweight and obesity in the US was 44.9% in
1960-62 which increased to 67.9% in 2007-08 (Figure 1). The increasing prevalence of
obesity is also a problem worldwide. According to the World Health Organization
(WHO), approximately 1.6 billion and 400 million adults were overweight and obese
respectively in the world in 2005 [3].
According to NHANES data, the prevalence of obesity among children and
adolescents (defined as BMI greater than or equal to 95th percentile from the CDC growth
charts) aged 2-19 years in US was 16.9% in 2007-2008 [4]. This is a significant increase
from the reported value of 5.5% for this group in 1976-1980.
Obesity increases the risk of premature death [5] as well as several comorbidities. These include cardiovascular diseases [6], type-2 diabetes [7], several forms
of cancer [8], obstructive sleep apnea [9], osteoarthritis [10], asthma [11], depression [12]
and gallbladder disease [13]. Thus, parallel to the increase in obesity rates, the prevalence
3

Figure 1. Prevalence of overweight and obesity in the United States
Change in prevalence of overweight and obesity in US adults from 1960 to 2008 is
shown. Based on NHANES data from Flegal et al, 2010 [1]
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of diabetes and other co-morbid conditions have also increased during the last few
decades. For example, between 1980 and 2008, the number of US adults with type 2
diabetes has more than tripled (5.5 to 18.0 million) [14]. Worldwide, 150 million people
had type 2 diabetes in 2001, which was projected to increase to 220 million in 2010 and
300 million by 2025 [15].

Etiology of obesity
While obesity is a manifestation of chronic positive energy balance, its exact
etiology can be complex. Genes, environmental factors and gene-environment
interactions are important factors in this regard. Twin and family studies have shown that
genetic factors can account for 45–75% of the variation in BMI [16]. The two
conventional approaches for identifying genes associated with a trait of interest are
association studies and linkage analysis [17]. Using the former approach, where
associations between candidate genes and phenotypes are identified, several monogenic
forms of obesity have been discovered. These include mutations in leptin, leptin receptor,
pro-opiomelanocortin and melanocortin 4 receptor and syndromic forms of obesity
including Bardet-Biedl and Prader-Willi syndromes [18]. These single-gene syndromic
and non-syndromic forms account for about 5% of obese individuals. More recently,
large-scale genome-wide association studies have identified common genetic variations
associated with differences in adiposity across populations. Single nucleotide
polymorphisms (SNPs) of the fat mass and obesity associated (FTO) gene have been
identified in this manner. However, such loci with risk alleles for obesity only account for
5

around 2% of the variation of BMI. Thus, it is likely that alleles with very low
frequencies might explain at least part of the missing genetic contribution [19].
Although genetic factors are responsible for several forms of obesity, they alone
are unlikely to be responsible for the recent increase in obesity trends. In this regard,
environmental factors and gene-environment interactions become important factors for
the recent rise in obesity rates. Indeed, physical activity is decreasing in the society
especially among children [20]. Moreover, food availability has also become plentiful
during this period. In this context, it is possible that the ‘thrifty genotype’ in some
individuals interacts with these environmental conditions to manifest as obesity.

Obesity and metabolic syndrome
Obesity is associated with the metabolic syndrome, which is characterized by
hyperglycemia, abdominal obesity, hypertension, elevated plasma triglycerides and
reduced plasma high-density lipoprotein cholesterol (HDL) levels [21]. Individuals with
the metabolic syndrome frequently have pro-inflammatory and pro-thrombotic metabolic
profiles and are at a higher risk of developing type-2 diabetes and cardiovascular disease.
Recent evidence has causally linked obesity and increased adiposity to the pathogenesis
of metabolic syndrome and type 2 diabetes. Furthermore, adipose tissue dysfunction and
inflammation play major roles in these disorders.

Adipose tissue dysfunction in obesity
Disclosure: The work described in this section has been submitted for the following
publication, with minor modifications in the numbering of tables and figures:
6

“Kalupahana NS, Claycombe KJ and Moustaid-Moussa N. Omega-3 fatty acids alleviate
adipose tissue inflammation and insulin resistance: mechanistic insights. Submitted to
Advances in Nutrition”

Structure and function of adipose tissue
White adipose tissue is the major site for storage of excess energy in the body. It
is composed of adipocytes, an extra-cellular matrix, vascular and neural tissues and other
cell types [22]. These other cell types include preadipocytes, fibroblasts, stem cells and
immune cells such as macrophages and T cells. Adipose tissue secretes numerous
bioactive peptides collectively known as adipokines [23]. Examples include hormones
involved in energy homeostasis such as leptin, peptides involved in glucose homeostasis
such as adiponectin, resistin, apelin and visfatin, chemokines such as monocyte
chemotactic protein (MCP)-1 and interleukin (IL)-8, pro-inflammatory cytokines such as
IL-6, IL-1, angiotensin (Ang)-II and tumor necrosis factor (TNF)-α, and antiinflammatory peptides such as IL-10. Thus, adipose tissue is now considered to be an
endocrine organ which plays a major role in energy balance, glucose homeostasis, blood
pressure regulation and immune function [24]. A detailed list of adipokines and their
functions are given in Table 1.

Distribution of body fat
The distribution of white adipose tissue throughout the body can be divided into
two major divisions, viz. subcutaneous and visceral adipose tissue [25]. Subcutaneous fat
7

is mainly present in the gluteofemoral region, back and anterior abdominal wall, while
visceral fat is present intra-abdominally. Since visceral fat is present around internal
organs, and because it can drain directly into the liver via the portal vain, it is considered
to be more metabolically active than subcutaneous fat. Moreover, the adipokine profile is
different between the two fat depots, with the visceral depot having a more proinflammatory adipokine profile [26]. Thus, in contrast to subcutaneous fat, excessive
accumulation of visceral fat is considered to be detrimental to metabolic health [27].
Indeed, epidemiological studies have shown that central obesity (increased visceral fat),
is associated with overall mortality, insulin resistance, type 2 diabetes mellitus and
cardiovascular disease [5]. Rodent models are frequently used to study mechanisms of
obesity and its co-morbidities. In these animals, the inguinal and gonadal fat pads are
considered to be comparable to subcutaneous and visceral fat depots respectively in
humans.

Adipose tissue inflammation in obesity

Excessive triglyceride accumulation within adipocytes, as a result of positive
energy balance, leads to adipocyte hypertrophy and a dysregulation of adipokine
secretory patterns. This has been primarily linked to an unbalance between secretions of
pro- vs. anti-inflammatory adipokines. Specifically, adipocyte hypertrophy is
characterized by increased secretion of pro-inflammatory adipokines such as TNF-α [28],

8

Table 1. Major adipokines and their functions
Adipokine
Leptin
Adiponectin
Resistin
Angiotensin II
MCP-1
TNF-α
PAI-1
IL-6
IL-10
Visfatin
Apelin
RBP-4
VEGF
NGF
IL-1
IL-1Ra
Vaspin
Omentin
Neuropeptide Y
Hepcidin
IL-8
IL-18
Thrombospondin-1
Chemerin

Physiological effects
Reduces energy intake and increases expenditure,
angiogenesis and hematopoiesis, immune functions
Improves insulin sensitivity, anti-inflammatory, antiatherogenic, promotes fatty acid oxidation
Promotes insulin resistance
Vasoconstriction, sodium and water retention, increases
blood pressure, promotes insulin resistance
Promotes macrophage infiltration and insulin resistance,
pro-inflammatory, chemotaxic
Pro-inflammatory, promotes insulin resistance
Pro-thrombotic, pro-inflammatory
Pro-inflammatory
Anti-inflammatory
Insulin-mimetic actions, cell proliferation
Promotes glucose uptake, angiogenesis
Promotes insulin resistance
Angiogenesis
Neuronal development
Pro-inflammatory
Anti-inflammatory
Insulin-sensitizing effects
Regulates insulin action
Energy homeostasis, proliferation of preadipocytes
Pro-inflammatory
Pro-inflammatory, chemotaxic
Pro-inflammatory
Pro-inflammatory
Impairs glucose tolerance

Ref.
[29]
[30]
[31]
[32]
[33]
[34]
[35]
[36]
[37]
[38]
[39]
[40]
[41]
[42]
[43]
[43]
[44]
[45]
[46]
[47]
[48]
[49]
[50]
[51]

MCP-1 – monocyte chemotactic protein-1, TNF-α – tumor necrosis factor-α, PAI-1 –
plasminogen activator-1, IL – interleukin, RBP-4 – retinol binding protein-4, VEGF - vascular
endothelial growth factor, NGF – nerve growth factor; IL-1Ra – IL-1 receptor antagonist
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IL-6 [26], angiotensinogen, Ang II [52], leptin [53] and MCP-1 [54] and reduced
secretion of anti-inflammatory adipokines such as adiponectin [55] and IL-10.
Thus, obesity is associated with a chronic low-grade inflammation in the adipose
tissue [56, 57]. Both adipocytes and macrophages are considered to be the source of
proinflammatory cytokines in obesity [23, 58]. Major cellularity and immune changes
between lean and obese adipose tissue is illustrated in Figure 2.
While the exact trigger for the onset of adipose tissue inflammation is hitherto unknown,
several possible mechanisms have been suggested. In a state of positive energy balance,
adipose tissue expands to accommodate the storage of excess triglycerides. Adipose
tissue remodeling via degradation of the extracellular matrix (ECM) and adipogenesis are
two key processes in this expansion. Matrix metalloproteinases (MMP) and tissue
inhibitors of MMPs (TIMP) play important roles in ECM degradation and adipose tissue
remodeling [59, 60]. Defective adipose tissue expansion as a result of dysregulation of
any of the above factors could lead to adipocyte injury, death and inflammation. For
example, factors that promote adipose tissue fibrosis such as secreted protein acidic and
rich in cysteine (SPARC) are associated with obesity and adipose tissue inflammation
[61].
Rodent studies show that increasing adipose tissue mass without a similar
magnitude increase in supporting vasculature could lead to tissue hypoxia, triggering the
expression of hypoxia-inducible factor-1 and inflammatory genes [62]. Similarly, oxygen
partial pressure in subcutaneous adipose tissue negatively correlates with adiposity in
humans [63]. Thus, hypoxia could be a trigger for adipose tissue inflammation.
10

Figure 2. Immune cell infiltration of adipose tissue in obesity
Lean individuals have higher M2/M1 macrophage, TH2/TH1 T cell and Regulatory /
Effector T Cell ratios (A). Excessive triglyceride accumulation leads to adipose tissue
remodeling, relative hypoxia and ER stress which trigger production of chemokines and
changes in the above cell ratios culminating in increased production of pro-inflammatory
adipokines and reduced production of anti-inflammatory adipokines (B). MMPs-Matrix
metalloproteinases, SPARC- secreted protein acidic and rich in cysteine
11

Further, several animal and human studies have suggested that adipose tissue
endoplasmic reticulum (ER) stress is another important triggering event for subsequent
inflammation in obesity [64-67].
While there is evidence that adipose tissue expansion per se is an important
initiator of the inflammatory processes during the development of obesity, other lines of
evidence suggest that dietary fats could also trigger this process. Indeed, the nuclear
factor kappa B (NF-kB) pathway in the visceral adipose tissue is activated 2 hours after
consumption of a meal rich in saturated fatty acids in rodents [68]. Other studies have
shown similar chronic effects of fatty acids (saturated fatty acids and conjugated linoleic
acid) in triggering inflammation in the adipose tissue [69-71]. Given that these fatty acids
are ligands for Toll-like receptors (TLR) 2 and 4, and since TLR 2 and 4 are expressed in
human adipocytes [72], it is likely that the effect of saturated fats on adipose tissue
inflammation is mediated via these receptors. Indeed, obesity-induced adipose tissue
inflammation is attenuated in mice with a mutation in TLR-4 [73].
Other pattern recognition receptors of the innate immune system such as Nod-like
receptors are also implicated in obesity and high saturated fat-associated adipose tissue
inflammation [74]. Conversely, there are studies showing that adipose tissue
inflammation can be reduced without changing adipose mass [75, 76]. This is also
consistent with our recent findings that omega-3 polyunsaturated fatty acids reverse highfat induced metabolic disorders and adipose inflammation [77]. Taken together, the
current research suggests a role of dietary fat in the onset of adipose tissue inflammation.

12

Adipose tissue inflammation in obesity is characterized by macrophage
infiltration [56, 78] (Figure 2). Adipose tissue macrophages (ATM) are classified into
two main types. M1 or classically activated macrophages are stimulated by interferon
(IFN)-γ and lipopolysaccharide (LPS) and produce pro-inflammatory cytokines such as
TNF-α, IL-6 and IL-1 and reactive oxygen species such as NO (Figure 2). M2 or
alternatively activated macrophages are activated by IL-4 and IL-13 and express antiinflammatory factors IL-10, transforming growth factor (TGF)-β, IL-1 receptor
antagonist-a, IL-4 and arginase [79, 80]. Phenotypically, murine ATM express F4/80
antigen. The murine M1 ATM highly express cluster of differentiation (CD) 11c, while
the M2 express macrophage galactose N-acetyl-galactosamine specific lectin 1 (MGL1)
[81]. In contrast, human ATM express CD14, while CD11c is only poorly expressed.
Human ATM also express CD206, CD209 and CD163 [81].
Obesity induces an M2 to M1 shift in ATM populations, characterized by a
reduction in anti-inflammatory IL-10 and arginase production and an increase in proinflammatory TNF-α production [82] (Figure 2). This increase in M1 ATM could be due
to either a ‘phenotypic switch’ from M2 to M1, or due to additional recruitment of M1
macrophages from blood vessels. Lipotoxicity of macrophages seems to play a major role
in the phenotypic switch of M2 to M1 [83]. Detailed mechanisms of the M2 to M1 switch
have previously been reviewed by Olefsky et al. [84]. Briefly, TLR4 ligands such as
saturated fatty acids activate NF-kB and activator protein 1 transcription factors, leading
to increased production of proinflammatory cytokines such as TNF-α, IL-6 and IL-1
giving rise to the M1 phenotype. In the lean adipose tissue, this is prevented by
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repression of TLR4-responsive genes by nuclear receptor corepressor (NCoR)
complexes. Peroxisome proliferator-activated receptor (PPAR) γ along with IL-4 and IL13 prevent the signal-dependent turnover of NCoR and thus maintain the M2 phenotype.
Evidence for M1 recruitment originated from studies showing increased MGL1C-C motif chemokine receptor (Ccr)+ macrophages recruited around necrotic adipocytes
in high-fat diet-fed mice; while the MGL+ ATM levels remain unchanged [85]. Adipose
tissue from obese animals expresses high levels of chemokines such as MCP-1,
Macrophage inflammatory protein-1α (MIP-1α) and regulated upon activation, normal Tcell expressed and secreted (RANTES), chemokine receptors such as Ccr2 and Ccr5 [56]
and adhesion molecules such as P-selectin glycoprotein ligand-1 (PSGL-1) [86]. The
expression of these chemokines, chemokine receptors and adhesion molecules play a
major role in recruitment of macrophages to adipose tissue in obesity. Indeed, mice
overexpressing MCP-1 in the adipose tissue have higher macrophage infiltration of
adipose tissue, while MCP-1 knockout mice are protected from high-fat diet-induced
adipose tissue macrophage infiltration [87]. Similarly, Ccr2 deficient mice also have
lower ATM numbers [88], while PSGL-1 knockout mice are protected from HF dietinduced adipose inflammation [86]. In contrast, however, MIP-1α-deficient mice are not
protected against high-fat diet induced adipose tissue macrophage infiltration [89]. Thus,
MCP-1 is a key mediator of the initiation of adipose tissue inflammation in obesity.
However, the exact mechanism of MCP-1 induction in obesity is not known. It is likely
that adipocyte hypertrophy plays a role in this, since adipocyte size positively correlates
with MCP-1 expression in humans [90, 91].
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Recent evidence also points towards involvement of T cells in the adipose tissue
inflammation in obesity [92]. Nishimura et al. showed that CD8 (+) effector T cells
infiltrate the WAT in high-fat fed mice, with a concurrent reduction in CD4 (+) helper
(Th) and regulatory (Treg) T cells [93]. Moreover, these changes occur before the
adipose tissue infiltration with macrophages. The adipose tissue infiltration of
macrophages is prevented by genetic depletion of CD8 (+) T cells. Feuerer et al. showed
that the number of Treg cells in the WAT of obese mice is significantly lower than in
lean ones [94]. Winer et al. showed that obese mice have a higher Th1/Th2 ratio
promoting IFN-γ secretion from adipose tissue [95] (Figure 2). Taken together, this
suggests that T cells are early modulators of adipose tissue inflammation in obesity. The
cytokine profile of these T cells could play an important role in determining the M1/M2
phenotype of ATMs.

Role of adipose tissue in insulin resistance
Insulin resistance is defined as an inadequate response by insulin-sensitive tissues
(liver, skeletal muscle and adipose tissue) to normal circulating levels of insulin [96]. At
physiological levels, insulin inhibits hepatic glucose production, promotes skeletal
muscle glucose uptake and inhibits lipolysis. Thus, insulin resistance leads to
impairments in insulin-mediated suppression of hepatic glucose production, skeletal
muscle glucose disposal and inhibition of lipolysis, leading to relative hyperglycemia and
increased plasma levels of non-esterified fatty acids (NEFAs). In response to the relative
hyperglycemia, there is a compensatory response by the pancreatic β cells, which secrete
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more insulin. This hypersecretion of insulin in turn increases skeletal muscle glucose
uptake and inhibits hepatic glucose production to maintain normoglycemia. Thus, insulin
resistant individuals maintain normoglycemia through overproduction of and secretion of
higher insulin levels. Long term insulin resistance and hypersecretion of insulin
eventually leads to pancreatic β cell failure. These events results initially in prediabetes
and glucose intolerance and later progresses to hyperglycemia and type-2 diabetes [97].
Insulin resistance can be either genetic or acquired. But in most instances it is due
to an interaction of environmental / lifestyle factors with genetic factors. Obesity,
sedentary lifestyle and aging are known causes of insulin resistance [96]. The
contribution of adipose tissue to the pathogenesis of insulin resistance and metabolic
syndrome is reviewed in detail below.

Molecular mechanisms of insulin resistance
Insulin exerts its physiological actions on insulin-sensitive tissues via activation
of a cascade of intracellular signaling events, all of which have been previously reviewed
[98, 99]. Insulin binds to the insulin receptor, which induces autophosphorylation as well
as phosphorylation of downstream substrates including the insulin receptor substrates
(IRS) at tyrosine residues. The family of IRS proteins contains 6 members. IRS-1 and
IRS-2 are widely distributed, while IRS-3 is present mainly in adipocytes and brain. IRS4 is expressed in embryonic tissue. Tyrosine phosphorylation of the IRS leads to its
binding to Src-homology-2 domain (SH2 domain) of the regulatory subunit of
phosphatidylinositol 3-kinase (PI3K). This leads to activation of the catalytic subunit of
16

PI3K, which in turn catalyses the formation of lipid second messenger PIP3. This allows
proteins with pleckstrin-homology domains (PH domains) to bind to PIP3, leading to their
activation. Activation of 3-phosphoinositide-dependent protein kinase 1 (PDK1), leads to
activation of Akt / protein kinase B (PKB). Akt/PKB is a serine/threonine kinase which
targets several downstream proteins. Activation of Rab small GTPases via
phosphorylation and inactivation of AS160 by Akt, leads to cytoskeletal reorganization
and translocation of glucose transporter-4 (Glut-4) into the cell membrane. This leads to
increased glucose entry into cells.
Akt also phosphorylates and deactivates glycogen synthase kinase 3 (GSK3),
which leads to activation of glycogen synthase and subsequent glycogen synthesis. Akt
also regulates transcription of several genes involved in gluconeogenesis and lipogenesis
via control of winged helix or forkhead (FOXO) class of transcription factors. For
example, Akt inhibits the FOXO1-mediated activation of hepatic guconeogenic genes in
the liver [98]. Thus, the net effect of these signaling cascades is an increased glucose
entry into cells as well as increased flux of glucose into intra-cellular metabolic pathways
(skeletal muscle and adipose tissue) and reduced gluconeogenesis (liver).
Downregulation of insulin receptor protein level, as seen in obesity, can result in
insulin resistance [98]. Defective insulin signaling at various levels of the above cascade
is also known to be associated with insulin resistance. A reduction in IRS protein levels is
also associated with insulin resistance. Hyperinsulinemia itself can reduce IRS protein via
transcriptional regulation [99]. Suppressor of cytokine signaling-3 (SOCS-3) sterically
blocks the interaction between insulin receptor and IRS and contributes to insulin
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resistance [100]. Serine phosphorylation of IRS by free fatty acids, cytokines [101] and
activation of NF-kB-mediated inflammatory pathways [102] is also known to induce
insulin resistance. SOCS1 and 3 are also known to induce degradation of IRS [103].
Further downstream, higher expression of the regulatory subunit of PI3K is also
associated with insulin resistance [104].

Proposed mechanisms for obesity-induced insulin resistance
Obesity induces insulin resistance in skeletal muscle, liver and adipose tissue
[84]. Several models have been put forward to explain mechanisms of obesity-induced
insulin resistance. The chronic low-grade inflammation occurring in adipose tissue is
considered to be a major factor in the pathogenesis of obesity-induced insulin resistance.
There are several lines of evidence to support this model. First, adipose specific
overexpression of proinflammatory cytokines such as MCP-1 or Agt induces whole-body
insulin resistance [87, 105]. Second, neutralization or knock down of inflammatory
mediators such as TNF-α, MCP-1, Ccr-2 and PSGL-1 protects rodents from HF dietinduced insulin resistance [34, 86-88]. Finally, overexpression of anti-inflammatory
adipokines such as adiponectin protects rodents from HF diet-induced insulin resistance
[106].
Increased pro-inflammatory cytokines can induce insulin resistance by several
mechanisms. As outlined earlier, pro-inflammatory cytokines can induce SOCS3
expression, which in turn can inhibit insulin signaling by inhibiting IRS action [100].
Pro-inflammatory cytokines also activate numerous intracellular serine kinases such as
jun N-terminal kinase (JNK) and inhibitor of κB kinase (IKK). These serine kinases can
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also inhibit insulin signaling at various levels [102]. Indeed, JNK1 or IKK-β knockout
mice and mice with adipose specific JNK inactivation are protected from insulin
resistance [107-109]. Finally, increased circulating free fatty acid levels due to adipose
tissue insulin resistance can in turn inhibit insulin signaling via serine phosphorylation of
IRS [101] and lead to insulin resistance in skeletal muscle and liver.
While the imbalance of pro- and anti-inflammatory adipokines can induce insulin
resistance via paracrine effects, the endocrine effects of these adipokines are especially
important in the development of insulin resistance in skeletal muscle and liver [34]. For
example, circulating levels of adiponectin, an adipokine exclusively secreted by the
adipose tissue, are positively correlated with insulin sensitivity in both humans and
rodents [110]. Moreover, individuals with high plasma adiponectin levels have a lower
risk of developing type-2 diabetes [111]. Finally, abdominal adiposity correlates with
plasma C-reactive protein (an acute-phase protein) levels, indicating that systemic
markers of inflammation are also increased with obesity [112]. While adipose tissue
inflammation in obesity plays a key role in the development of insulin resistance, adipose
inflammation in the absence of obesity does not seem to induce insulin resistance [113].
Thus, it is important to use mouse models with at least some degree of obesity when
studying the contribution of individual inflammatory mediators to insulin resistance.
Increased lipid deposition in skeletal muscle and liver is also considered to be a
factor linked to the pathogenesis of insulin resistance [96]. Indeed, obese insulin sensitive
individuals have lower skeletal muscle and liver lipids than obese insulin resistant
individuals [114]. This ectopic lipid deposition is attributed to the inability of the adipose
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tissue (mainly subcutaneous) to store excess energy due to reduced differentiation /
remodeling capacity. Insulin resistance in adipocytes leading to increased lipolysis and
plasma free fatty acid levels also contributes to lipid accumulation in these tissues. This is
also characterized by increased visceral fat mass. While the exact mechanism of these
defects in adipogenesis / remodeling is not known, pro-inflammatory cytokines such as
TNF-α are implicated because of their known inhibitory effects on adipogenesis [115], in
a PPARγ-dependent manner. Conversely, PPARγ agonists such as thiazolidinediones are
known to increase both adipogenesis and insulin sensitivity [116].
While it was initially hypothesized that increased fatty acid availability to skeletal
muscle inhibits glucose utilization via inhibition of key glycolytic steps (Randle
hypothesis), current evidence suggests that this is related to impairments in glucose
transport due to defective insulin signaling [117]. Indeed, increased lipid accumulation in
the liver and skeletal muscle is associated with increased fatty acid flux, which leads to
excessive accumulation of fatty acid intermediates such as ceramide [96]. These lipid
intermediates activate intracellular serine kinases which can lead to inhibition of insulin
signaling. Ceramide can also directly inhibit Akt [118]. Indeed, pharmacological
inhibition of ceramide synthesis protects rodents from obesity-associated insulin
resistance.

Role of the renin angiotensin system in the pathogenesis of insulin
resistance in obesity
Disclosure: The work described in this section has been submitted for the following
publication, with minor modifications in the numbering of tables and figures:
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“Kalupahana NS and Moustaid-Moussa N. The renin-angiotensin system: a link between
obesity and insulin resistance. Submitted to Obesity Reviews”

The renin angiotensin system (RAS) is traditionally known for its role in
regulation of blood pressure, fluid and electrolyte balance [119]. Angiotensinogen (Agt),
the main precursor peptide of this system, undergoes enzymatic cleavage by renin and
angiotensin-converting enzyme (ACE) to form angiotensin II (Ang II), the main effector
peptide of this system. Ang II exerts its physiological effects via two G-protein coupled
receptors, viz. Ang II type 1 (AT1) and type 2 (AT2) receptors. In addition to the systemic
RAS, several local ones also exist in organs such as brain, pancreas, heart and adipose
tissue [32]. Because Ang II increases blood pressure through AT1, ACE inhibitors
(ACEI) and AT1 blockers (ARB) are clinically used as anti-hypertensive agents.
Interestingly, epidemiological studies have shown that patients on ACEI or ARB
have a lower risk of developing type 2 diabetes compared to ones treated with other antihypertensive medications [120]. Subsequent randomized controlled trials have also
shown that RAS blockade improves glycemic control [121] and lowers the risk of
developing type 2 diabetes [122]. Because there is evidence for RAS overactivation in
obesity, and because RAS blockade improves insulin resistance, it is possible that RAS is
implicated in the pathogenesis of insulin resistance in obesity. Evidence for this
hypothesis, with specific emphasis on the role of adipose RAS on the pathogenesis of
insulin resistance is reviewed.
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Components of the RAS
Components of the classical RAS are well characterized. The common precursor
of all bioactive angiotensin peptides is Agt (Figure 3). It is mainly secreted by the liver in
lean individuals. Adipose tissue is another important source of Agt, especially in obese
individuals [123]. Agt is cleaved by the enzyme renin to form angiotensin I (Ang I).
Renin is mainly produced by the kidneys, and is a regulatory step in the RAS. Renin can
also bind to the renin receptor, and increase the catalytic efficiency of Ang I formation
[124]. Ang I is subsequently cleaved by ACE, present mainly in the lung and vascular
endothelium, to produce Ang II. Alternatively, Ang II can also be formed by the action of
cathepsins and chymase, especially in local RAS [119].
Ang II is the main effector peptide of the RAS, which exerts its effect via two Gprotein-coupled receptors (GPR) AT1 or AT2. Stimulation of AT1 induces
vasoconstriction and aldosterone secretion from the adrenal cortex, resulting in increased
blood pressure and sodium and water retention. Stimulation of AT2 generally exerts
blood pressure lowering effects. Ang I and Ang II can be cleaved to angiotensin (1-9) and
(1-7) respectively by the action of recently discovered enzyme ACE2 (Figure 3).
Angiotensin (1-7) can act on another GPR, the Mas receptor. Ang II is subsequently
degraded by aminopeptidases to produce angiotensin III and IV. Angiotensin IV acts on
the AT4 receptor. Most components of the systemic RAS are also found in the adipose
tissue [125]. Additionally, Agt can be cleaved by cathepsins and chymase to produce Ang
II, bypassing the renin-ACE axis in the adipose tissue [125]. Thus, Agt production is a
regulatory step in the adipose RAS.
22

Figure 3: Components of the renin-angiotensin system
Angiotensinogen is cleaved by renin and angiotensin converting enzyme (ACE) to form
angiotensin (Ang) I and II respectively. Ang II acts via Ang II type 1 (AT1) or type 2
(AT2) receptors to exert its physiological actions. Ang I and II can also be cleaved by
ACE2 to form Ang (1-9) and (1-7), which in turn can act on the Mas receptor. Ang II is
degraded to Ang III and IV. The latter can act on the AT4 receptor. Renin can also act on
the renin / pro-renin receptor (R/PR).
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Association between RAS and obesity
Several polymorphisms of RAS genes are associated with body weight and
adiposity. For example, the insertion/ deletion polymorphism (I/D) of ACE is associated
with overweight and abdominal adiposity in Italian men [126]. Further, the M235T
polymorphism of AGT is associated with visceral obesity in Japanese [127] and
subcutaneous adipocyte size in French [128] women.
Obesity is also associated with overactivation of both systemic and adipose RAS
in humans and animals (Table 2). In humans, obesity is associated with increases in
plasma Agt, renin, ACE and Ang II (Table 2). The elevation of plasma Ang II following
beta-adrenergic stimulation is also greater in obese than lean individuals [129].
Subcutaneous adipose tissue renin, ACE and AT1 expression is also increased in obesity.
Most, but not all studies show that adipose Agt expression is also higher in obese humans
(Table 2). Moreover, weight-loss leads to reductions in plasma Agt, renin, ACE and
adipose Agt levels [130]. Animal studies, in contrast, show that the direction of change in
RAS components in obesity is strain-dependent (Table 2). Similar to humans, most dietinduced obese rodent models show overexpression of both systemic and adipose RAS
components. When genetic models of obesity are considered, ob/ob and db/db mice show
activation of systemic and adipose RAS, while the obese (fa/fa) Zucker rat, viable yellow
mouse and Wistar fatty rat exhibit lower expression of systemic and adipose RAS
components compared to lean littermates (Table 2). Taken together, this highlights the
importance of selecting the correct animal model to study the role of systemic and
adipose RAS in obesity.
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Table 2. Association of RAS components with obesity
Subjects
RAS component
Association with obesity
Positive
No association Negative
Humans
Plasma Agt
[131], [130],
[129], [136]
[132], [133],
[134], [135]
Plasma Renin
[130], [137],
[138], [139]
Plasma ACE
[130], [135]
Plasma Ang II
[130]
[129]
Plasma Ang II
[129]
(sympathetic
stimulated)
Adipose Agt
[129], [52],
[128], [136]
[130], [142]
[140], [141]
Adipose AT1
[136], [142]
Adipose Renin
[142]
Adipose ACE
[142]
Animals

Plasma Agt
Plasma Ang II

Plasma renin
Adipose Agt

Adipose AT1
Liver Agt

DIO-SD [143],
DIO-B6 [123]
DIO-SD [143],
SF-Wistar rat
[145]
SD DIO [146],
dogs [147]
Ob/ob, Db/db
[150], ZF [151],
DIO-SD [143],
DIO-B6 [152],
[123] FF-SD
[153]
FF-SD [154]

ZF [144]

ZF [148], [149]
FF-SD [154]

ZF, Viable
yellow [32],
Wistar fatty rat
[155]
ZF [156]

ZF, Viable
yellow [32],
[151], DIO-SD
[143], DIO-B6
[123, 152]
DIO – diet-induced obese; SD- Sprague-Dawley rat; B6- C57BL/6J mouse; ZF – Zucker
fatty rat; SF – sucrose-fed; FF- fructose-fed
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While there are discrepancies concerning adipose Agt expression in animal
models of obesity, these studies consistently report no change in hepatic Agt production
in obese compared to lean animals (Table 2). Considering that plasma Agt levels are
increased in obesity, with relatively unchanged hepatic Agt production, this highlights the
potential contribution of adipose-derived Agt to systemic levels. Indeed, adipose tissue
may contribute up to 30% of plasma Agt level in obesity [157]. Further, studies in
transgenic mice overexpressing Agt in adipose tissue demonstrate that overproduction by
only about 20% can drive both adipocyte hypertrophy and high blood pressure [157].
Several studies have reported effects of overactivation of various RAS
components or blockade on body weight and adiposity. Surprisingly, systemic RAS
overactivation via chronic Ang II infusions or renin overproduction induces weight loss,
rather than weight gain, in rodents (Table 3). This is attributed to initial reduction in
energy intake and subsequent increase in energy expenditure [158, 159]. In contrast,
adipose specific RAS overactivation via increased expression of Agt leads to increased
adiposity [157]. Thus, it appears that paracrine/autocrine actions of Ang II in adipose
tissue maybe important for fat mass expansion associated with RAS overexpression.
Pharmacological RAS blockade via ACE inhibitors or ARB reduce adiposity in
rodents [160, 161], but not in humans. RAS blockade via genetic deletion of Agt, renin,
ACE, AT1 or AT2 also protect rodents from diet-induced obesity (Table 3), suggesting a
role of RAS in the development of obesity. Deficiency of Mas receptor, however,
increases adiposity in rodents, suggesting a potential beneficial role for the Ang (1-7)mas axis on adiposity [162].
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Table 3: Effects of RAS manipulation in humans and animals

Manipulation

Ang II infusion
(acute – humans)
Ang II infusion
(chronic – rodents)
Renin overexpression
Ang (1-7) infusion
(rodents)
Renin knockout

Body
weight/
adiposity

Insulin
sensitivity

Adipocyte
size

Adipocyte
number

Reference

-

-

-

-

[163], [164],
[165], [166]
[167], [168],
[158], [169],
[159]
[170], [171]

+

[172]

+

-

+

-

[173]

-

[174]

Agt knockout

-

ACE knockout

-

+

AT1 knockout

-

+

-

AT2 knockout

-

+

-

+

[178]

Adipose Agt
overexpression
Mas genetic deletion

+

+

-

[157], [179]

Adipose Agt
overexpression + AT2
knockout

-

+

[175]
[176], [177]

[162]

-

+ positive association; - negative association
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[179]

RAS and insulin resistance
Numerous genetic studies have shown associations between polymorphisms in
RAS genes and glucose homeostasis. The DD genotype of the ACE I/D polymorphism is
associated with glucose intolerance and insulin resistance in several adult [180, 181] and
infant [182] populations. Further, the AGT T174M and M235T polymorphisms are
significantly associated with metabolic syndrome in aboriginal Canadians [183] and
glycated hemoglobin in neonates [184], respectively. The plasma level of insulin
sensitizer adiponectin is also associated with the AT1 A1166C polymorphism in young
women [185]. Having multiple risk genotypes of RAS polymorphisms significantly
increases the risk of type 2 diabetes [186].
The strongest clinical evidence for an association between systemic RAS and
insulin resistance originates from clinical trials which have shown that RAS blockade
reduces the risk of developing type 2 diabetes [119, 187]. For example, there was a 14%
lower risk of developing type 2 diabetes for patients on ACEI vs. conventional treatment
(diuretics / beta blockers) in the in the Captopril Primary Prevention Project (CAPPP)
[122]. In the Heart Outcomes Prevention Evaluation (HOPE) trial, there was a 34% risk
reduction in the Ramipril (ARB) group compared to the placebo control group [187].
Pharmacological RAS blockade also improves insulin sensitivity in several rodent models
of obesity or insulin resistance [188, 189] Moreover, rodents with genetic deletions of
Agt, renin, ACE, AT1 or AT2 show improvements in insulin sensitivity and/or resistance
to HF diet-induced insulin resistance (Table 3).
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Conversely, chronic overactivation of systemic RAS induces whole body insulin
resistance in rodents (Table 3). However, acute RAS overactivation via short-term Ang II
infusions increases glucose disposal, and improves insulin sensitivity in humans [163]
and rodents [190]. This latter phenomenon is attributed to acute haemodynamic
adaptations in the form of redistribution of blood flow to skeletal muscle in response to
increased Ang II levels [163, 164]. Since experimental chronic Ang II infusions are not
feasible in human studies, animal models have been used to study the effects of chronic
RAS overactivation. In these studies, chronic Ang II infusion induces skeletal muscle and
hepatic insulin resistance, giving rise to whole-body insulin resistance [167]. The
TG(mREN2)27 rat, another model of chronic systemic RAS overactivation, also develops
skeletal muscle and systemic insulin resistance [170]. The insulin resistance in these
animals is improved by either direct renin inhibition [191] or AT1 blockade [192].
The mechanisms of Ang II-mediated skeletal muscle insulin resistance have been
studied extensively. A summary is given in Figure 4. Muscle glucose uptake depends
upon glucose delivery, glucose transport across the cell membrane and glucose utilization
[193]. Of these processes, Ang II mainly impairs glucose transport and glucose utilization
by the skeletal muscle [194] (Figure 4). Ang II impairs glucose transport mainly via
inhibition of insulin signaling. Specifically, Ang II abolishes the insulin-mediated
tyrosine phosprorylation of IRS-1, activation of Akt and translocation of Glut 4 in L6
myocytes in vitro, in a NADPH oxidase and AT1-dependent manner [195]. This is also
dependent upon activation of the NF-kB pathway in skeletal muscle [196].
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studied extensively and was reviewed by Henriksen [197]. A summary is given in
Figure 5. Muscle glucose uptake depends upon glucose delivery, glucose transport across
the cell membrane and intracellular glucose trapping via phosphorylation of glucose,
which in turn is affected by

Figure 4. Mechanisms of Ang-II mediated skeletal muscle insulin resistance
Ang II activates NADPH oxidase via AT1. This leads to generation of reactive oxygen
species (ROS), which induce and activate nuclear translocation of NF-kB pathway. The
latter mediates transcription of cytokines such as TNF-α and IL-6 and subsequent binding
to their receptors. This binding induces serine kinases and SOCS3 expression, further
inhibiting the tyrosine phosphorylation of IRS-1. This leads to deactivation of
downstream insulin signaling and Glut-4 translocation, resulting in reduced glucose entry
in to the cell. ROS also inhibit mitochondrial biogenesis leading to reduced glucose
utilization.
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Similarly, defective insulin-stimulated phosphorylation of IRS-1, Akt and glycogen
synthase kinase-3beta [170] was reported in isolated skeletal muscle of the
TG(mREN2)27 rat. The Ang-II mediated inhibition of IRS-1 is also due to its
inactivation by serine phosphorylation or due to activation of protein tyrosine
phosphatase-1B [198]. It is likely that Ang II activates NADPH oxides via AT1, which
leads to increased production of reactive oxygen species (ROS). This activates the NF-kB
pathway, which increases transcription of cytokines such as TNF-α and IL-6. These
cytokines acting in a paracrine fashion, increase SOCS3 expression [199], which further
inhibits insulin signaling (Figure 4). In terms of glucose utilization, Ang II reduces
skeletal muscle mitochondrial content in an AT1 and AT2-dependent manner in rodents
both in vitro and vivo [200], an effect proposed to be mediated via ROS [200].
ACEI and ARB prevent these Ang II effects on insulin signaling and utilization
and improve skeletal muscle insulin sensitivity. An additional mechanism of ACEImediated improvement in insulin sensitivity is via prevention of the degradation of
bradykinin, a potent vasodilator and potentiator of insulin signaling [201]. This is
explained by the ability of ACE to degrade bradykinin (Figure 3), which is prevented by
ACE inhibition.
Additional mechanisms contributing to Ang II-mediated insulin resistance include
the ability of Ang II to increase hepatic glucose production [202], which can contribute to
whole-body insulin resistance. However, the exact mechanism responsible for this is not
known, although recent evidence suggests that Ang II might be implicated in the
development of hepatic steatosis [203]. Ang II’s actions on the endocrine pancreas may
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also play a role in defective glucose homeostasis associated with RAS overexpression.
Indeed, the endocrine pancreas expresses a local RAS which is involved in the regulation
of glucose-stimulated insulin secretion, insulin synthesis and pancreatic blood flow [204].
Further, RAS blockade improves islet morphology and function [205] and transfection of
ACE2 into pancreatic islets of db/db mice also improves glycemic control [206].
Unlike in skeletal muscle, Ang II does not induce insulin resistance in adipose
tissue [190]. Indeed, Ang II potentiates insulin-stimulated glucose uptake by adipocytes
[190] via activation of insulin signaling molecules in vitro [207]. However, adipose tissue
RAS could be important in the pathogenesis of systemic insulin resistance for several
reasons. First, adipose-derived Agt and Ang II contribute to systemic levels of these
hormones [208], which are increased in obesity [123]. Next, paracrine effects of Ang II
on adipose tissue alter the adipokine profile toward a pro-inflammatory phenotype, which
can then lead to skeletal muscle insulin resistance. For example, Ang II infusions reduce
plasma adiponectin levels in an AT1-dependent manner [209]. Finally, similar to several
pro-inflammatory cytokines, Agt is expressed higher in visceral compared to
subcutaneous adipose tissue [210]. Thus, it is important to discuss the adipose RAS in the
context of obesity and insulin resistance.

Role of Adipose tissue RAS in regulating adipose tissue function
In the adipose tissue, Agt is synthesized and secreted by adipocytes. Most of the
other RAS components necessary to produce Ang II are also present in the adipose tissue.
Thus, the presence of an adipose RAS is well established. In addition to the classical
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regulatory steps, Adipose RAS appears to be regulated at the level of Agt production,
which is controlled by hormones such as insulin, androgens and dexamethasone and
cytokines such as TNF-α [32, 210]. Indeed, insulin [211] and cytokine [212] response
elements have been reported in the Agt promoter.
Functionally, Ang II plays a role in energy sensing, as well as modulating fat
mass expansion via its effect on adipogenesis, lipogenesis and lipolysis. In genetically
obese mice, feeding increases adipose Agt expression, while fasting reduces it [150],
suggesting a role of Agt in energy sensing, possibly via the hexosamine pathway [213,
214]. It is plausible that in a state of acute energy influx to the adipose tissue, Agt
production leads to increased local Ang II levels, which in turn induces local
vasoconstriction resulting in lower lipolytic rates [215]. Conversely, in fasting conditions,
due to lower local Ang II levels, vasodilatation occurs, leading to increased rates of
lipolysis. These Ang II effects are mediated via AT1.
Ang II also increases lipogenesis via AT2 [216]. This is through induction of key
lipogenic enzymes such as glycerol-3-phosphate dehydrogenase. Consistent with these
effects, Ang II also potentiates insulin-stimulated glucose uptake by adipocytes [190].
Therefore, unlike in skeletal muscle, Ang II appears to enhance insulin action in
adipocytes in vitro. Taken together, the net paracrine effect of Ang II is to reduce
lipolysis and promote lipogenesis, ultimately increasing lipid storage and inflammation in
adipose tissue (Figure 5).
While acute changes in energy availability modulate adipose RAS activity, the
effects of chronic energy excess on it is inconsistent. While most studies report Agt
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Figure 5. Effects of Ang II and RAS blockade on adipose tissue function
Adipose tissue expansion during positive energy balance involves a combination of
adipocyte hypertrophy and hyperplasia. Adipogenesis via preadipocyte differentiation to
adipocytes results in adipocyte hyperplasia (A). Mature adipocytes secrete Agt, which is
converted to Ang II. Ang II acting on AT1 and AT2 inhibits preadipocyte differentiation.
Stimulation of AT2 also promotes lipogenesis, while activation of AT1 inhibits lipolysis.
Both processes promote adipocyte hypertrophy (B) which is associated with a proinflammatory adipokine profile.
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overexpression in human obesity, some have reported no change or a negative association
(Table 2). Since adipose Agt expression is acutely regulated by hormonal and nutritional
signals, this could be a confounding factor when studying the chronic effect of obesity on
adipose Agt expression. It is also possible that genetic factors, such as polymorphisms in
RAS genes also play a role in this discrepancy of results [128]. This is supported by the
fact that while adipose RAS is overactivated in most animal models of diet-induced
obesity, it is downregulated in some models with genetic forms of obesity (Table 2).
Given that not all obese individuals develop metabolic derangements, it is possible that
adipose RAS is also overexpressed in some, but not all, obese individuals. In this context,
it is important to study the effects of adipose RAS overactivation on adipose tissue
function and systemic insulin sensitivity, to elucidate its role in the pathogenesis of
metabolic derangements in obesity.
Since a reduced adipogenic capacity is linked to adipose tissue inflammation and
systemic insulin resistance in obesity [217], it is important to investigate the effects of
adipose RAS on both adipogenesis and lipogenesis, and conversely on both adipose
hyperplasia and hypertrophy. It is important to recognize that lipogenesis and
adipogenesis are distinct processes. The former refers to storage of lipids in adipocytes,
which is positively regulated by Ang II as described above. Adipogeneis refers to
formation of new adipocytes, either from preadipocytes or other precursors such as
mesenchymal stem cells. In a state of positive energy balance, adipose tissue expansion
occurs as a result of both these processes. Adipogenesis leads to adipocyte hyperplasia,
while lipogenesis leads to adipocyte hypertrophy. An inadequate adipogenic capacity,
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which is postulated to be linked to systemic insulin resistance, is characterized by
adipocyte hypertrophy and a lower adipocyte number.
RAS blockade via either ACEI or ARB results in smaller adipocyte size in
numerous rodent models of obesity [218-220]. Furthermore, ARB also increase the
number of small differentiated adipocytes in diabetic rats [161]. Both these findings
support the assertion that while RAS blockade inhibits lipogenesis, it also promotes
adipogenesis in vivo. However, these findings are confounded by the fact that some ARB
such as Losartan, activate PPARγ, an adipogenic transcription factor [221, 222]. Thus,
the effects of ARB on adipogenesis could be attributed to indirect effects.
Rodents with genetic deletion of renin, Agt, AT1 or AT2 also exhibit smaller
adipocytes (Table 3). Of these, mice lacking AT2 have a relative increase in adipocyte
number [178], suggesting an inhibitory effect of AT2 on adipogenesis.
The only animal model available to study the paracrine effects of RAS
overactivation on adipose tissue is the transgenic mouse model overexpressing Agt in the
adipose tissue (aP2-Agt mice). These mice become moderately obese and develop large
adipocytes [157]. Their adipocyte number is also reduced compared to wild-type mice
[179]. This suggests that increased local levels of Ang II inhibit adipogenesis. When
these mice are crossed with mice lacking the AT2 gene, their adipocyte number and size
becomes comparable to wild-type mice [179],

demonstrating a critical role of AT2 in

mediating Ang II’s inhibitory effects on adipogenesis. However, since their adipocyte
number is still lower than AT2 knockouts (with normal adipose Agt expression), AT1 also
seems to be, at least in part, involved in mediating Ang II’s anti-adipogenic effects.
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In vitro studies on Ang II’s effects on adipogenesis are inconsistent; practical
difficulties in dissociating adipogenesis from lipogenesis likely being the reason. Some
early studies show that Ang II increases murine preadipocyte differentiation via
prostacyclin and AT2-dependent manner [223]. However, it was later shown that Ang II
inhibits human mesenchymal stem cell differentiation into adipocytes in an AT2dependent manner [224]. There is also evidence that Ang II inhibits differentiation of
human [225-227] and 3T3-L1 [228] preadipocytes in an AT1-dependent manner in vitro.
While there is some evidence to suggest that Ang II exerts these effects via mitogen
activated protein kinase (MAPK) and extracellular signal-regulated kinase (Erk)
pathways [227], further studies are certainly warranted. Overall, this evidence suggests
that Ang II promotes lipogenesis and inhibits adipogenesis leading to an adipose tissue
phenotype characterized by large adipocytes (Figure 5). Whether this could be an
important mechanism for insulin resistance in conditions of adipose RAS overactivation,
remains to be tested.
Ang II promotes inflammation in several tissues [229]. Similarly, aP2-Agt mice
express higher levels of inflammatory genes in the adipose tissue [179]; however, it is
unclear whether this is a direct effect of Ang II. In vitro studies show that Ang II
increases pro-inflammatory cytokines IL-6 and IL-8 secretion from human adipocytes
[230] and MCP-1 from preadipocytes [231] in an NF-kB dependent manner. Conversely,
RAS blockade reduces MCP-1 expression and macrophage infiltration in HF diet-induced
obese mice [161]. Taken together this suggests that Ang II promotes adipose tissue
inflammation in an NF-kB-dependent manner (Figure 5). Further studies on the
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mechanisms of Ang II mediated stimulation of NF-kB in adipose tissue are thus
warranted.

Dietary approaches to ameliorate metabolic derangements in obesity
Obesity is causally linked to insulin resistance and metabolic syndrome (discussed
previously). Individuals with metabolic syndrome are at a higher risk of developing type2 diabetes and other chronic and inflammatory diseases. Dietary interventions are useful
in reducing the severity of these chronic diseases and in preventing them. Caloric
restriction is the primary dietary approach employed for weight loss purposes [232].
Furthermore, in recent years, bioactive components of foods, such as omega-3 fatty acids,
and various food-derived phytochemicals have gained popularity and are commonly
used as natural preventive therapies for chronic diseases [233]. In this section, we will
review the state of research interventions for metabolic disorders, using caloric restriction
and those using a bioactive compound, omega-3 polyunsaturated fatty acids.

Caloric restriction for improvement of insulin resistance and metabolic
derangements in obesity
Lifestyle modification, including restriction of energy intake, is as or more
effective than pharmacotherapy in preventing the progression of metabolic syndrome to
type 2 diabetes [234]. Caloric restriction leading to 5-10% loss of body weight, regardless
of the macronutrient composition of the diet, significantly improves glycemic control in
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obese individuals [235]. Even in patients with type-2 diabetes, caloric restriction and
weight loss improves insulin sensitivity [236]. Since dysfunctions in adipose tissue,
skeletal muscle, liver and endocrine pancreas alter glucose homeostasis in obesity, it is
important to investigate whether improved insulin resistance following caloric restriction
is accompanied with reversal of these tissue dysfunctions.
Enhanced insulin sensitivity following caloric restriction is at least in part due to
loss of body weight and adipose tissue mass. Indeed, some studies show that weight loss
consistently improves insulin sensitivity, regardless of whether it is induced by increased
energy expenditure or reduced energy intake [237, 238]. However, other weightindependent mechanisms might also operate. For example, obese individuals subjected to
short-term caloric restriction (1-week) exhibit improvements in insulin sensitivity despite
minimal weight loss [239]. This is also postulated to be a mechanism responsible for
rapid improvement of insulin sensitivity following bariatric surgery [239]. Moreover,
caloric restriction in non-obese animals increases longevity and delays the onset of
several chronic illnesses including type-2 diabetes [240]. In this context it is important to
understand the mechanisms of improvements in insulin sensitivity following caloric
restriction in obese individuals.

Caloric restriction and adipose tissue function
Caloric restriction leads to loss of adipose tissue mass in both subcutaneous and
visceral fat depots [241]. It also favorably alters plasma adipokine profile (Table 4).
Caloric restriction also reduces plasma leptin consistently across studies (Table 4) and
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Table 4 . Change in plasma adipokines following caloric restriction in obese humans
Adipokine

Increased

No Change

[242-246]

Leptin
Adiponectin

[244, 247-250]

[245, 246, 251-254]
[246]

IL-6

[242, 249, 255-257]
[242, 258]

RBP-4
Visfatin
TNF-α

Decreased

[259, 260]

[244]
[246, 257]

[255, 261]

PAI-1

[246, 262]

MCP-1

[248]

IL-6 – interleukin-6, RBP-4 – retinol binding protein-4, TNF – tumor necrosis factor,
PAI-1 – plasminogen activator inhibitor-1, MCP-1 – monocyte chemotactic protein-1

40

increases sensitivity to leptin [263]. The effect of caloric restriction on plasma
adiponectin level is variable, with some studies showing an increase while others
showing no effects of caloric restriction on this anti-inflammatory adipokine (Table 4).
Several reasons might account for these discrepancies. Fist, the restoration of plasma
adiponectin to non-obese levels could be age-dependent as evident by studies showing
that caloric restriction improves plasma adiponectin level in young, but not old rodents
[259]. Second, there could be a temporal change in adiponectin response to caloric
restriction [260]. Further, the magnitude of weight loss might influence adiponectin
response. Finally, given that fatty acids can modulate adipose tissue adipokine secretion,
the macronutrient composition of a caloric-restricted diet could also affect plasma
adiponectin levels. However, this latter possibility remains to be tested. When the effect
of caloric restriction on other adipokines are considered, it favorably changes plasma
RBP4, IL-6, visfatin, TNF-α, PAI-1 and MCP-1 levels (Table 4).
Caloric restriction reduces adipocyte size in humans [264, 265], probably due to
increased rates of lipolysis and a resistance to the insulin’s anti-lipolytic effects [266].
The anti-lipolytic α-2 adrenergic receptor expression is also reduced following caloric
restriction in obese individuals [267]. Caloric restriction also regulates expression of
genes involved in lipogenesis, fatty acid oxidation [268, 269] and fatty acid metabolism
in human adipose tissue. Examples include stearoyl-coenzyme A desaturase (SCD) and
diacylglycerol acyl transferase 2 (DGAT2) [270], both of which are downregulated by
caloric restriction.
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It is possible that caloric restriction also restores the adipogenic capacity affected by
obesity, by increasing the expression of several adipogenic factors [271] and the number
of small insulin-sensitive adipocytes in rats [272] suggesting an improvement in
adipogenic capacity.
Changes in expression of inflammatory genes in adipose tissue during caloric
restriction is variable, with some studies showing increased expression of IL-6 and TNFα [256] and others showing downregulation of inflammatory genes [273-275]. Moreover,
adipose tissue gene expression pattern does not always follow the direction of change in
plasma adipokines [246]. Therefore, it is possible that changes in adipose tissue
inflammation following caloric restriction are of a temporal nature. Recent evidence
confirms this as weight loss during caloric restriction is characterized by a dynamic
immune response. In obese mice on a high-fat diet, caloric restriction initially induces
macrophage recruitment into adipose tissue [276]. The macrophage number peaks at the
time of maximal lipolysis, suggesting a role of fatty acid flux in their recruitment. With
continued weight loss, the macrophage number decreases [276]. Similarly, in human
adipose tissue, macrophage markers increase during caloric restriction and decrease
during weight stabilization and maintenance [277], suggesting a dynamic immune
response.
Endoplasmic reticulum stress, another triggering factor of adipose tissue
inflammation, is alleviated by caloric restriction in obese mice [278]. Taken together,
while the adipose tissue inflammation associated with obesity seems to be alleviated by
caloric restriction, the exact nature of the dynamic immune response occurring during
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caloric restriction is yet to be fully characterized. Further, the effect of macronutrient
composition on adipose tissue inflammation also needs characterization.

Effects of caloric restriction on skeletal muscle and hepatic insulin sensitivity
Caloric restriction increases insulin-stimulated glucose disposal by the skeletal
muscle [279]. This is primarily due to enhancement of insulin signaling [236, 280] in an
Akt2-dependent fashion [281, 282]. Caloric restriction also results in increased glycogen
synthesis as well as fatty acid oxidation by the skeletal muscle [283]. Further, an increase
in skeletal muscle mitochondria content due to caloric restriction potentially leads to
increased glucose utilization and fatty acid oxidation by the muscle as well [284]. While
the exact mechanisms responsible for these changes are still unknown, but may be
attributed to reduced intramyocellular triglyceride (IMTG) content during caloric
restriction [236, 285]. Moreover, caloric restriction reduces the proportion of saturated
fatty acids in IMTG and muscle cell membranes [286, 287]. Other potential mediators of
caloric restriction-induced improvement in skeletal muscle insulin signaling include
growth factor receptor-bound protein 2 (Grb2). Expression of this protein is reduced in
caloric restriction. Further, experimental reduction of Grb2 enhances insulin signaling
and increases insulin-stimulated glucose uptake by myoblasts in vitro and protects mice
from high-fat diet induced insulin resistance [288].
Caloric restriction improves hepatic insulin sensitivity and restores the insulin
mediated suppression of hepatic glucose production [289]. These improvements are
primarily related to reductions in hepatic lipid [264, 290, 291] and visceral fat content
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[292]. Although the effects of caloric restriction on all components of hepatic insulin
signaling cascade have not been characterized, the obesity-induced increase in serine
phosphorylation of IRS is reported to be reversed by caloric restriction [293].
Caloric restriction also attenuates the glucose-stimulated insulin response [294,
295] suggesting a beneficial effect on the endocrine pancreas.

Caloric restriction and longevity
Caloric restriction, defined as dietary restriction without induction of
malnutrition, slows aging and extends longevity in different species including yeast, flies,
nematodes, rodents and non-human primates [296]. The effect of caloric restriction on
longevity of humans is still not clear [297], however studies are currently underway to
study this effect [298]. Several mechanisms have been proposed for mediating the
beneficial effects of caloric restriction on longevity. Reduced activation of nutrientsensing pathways is proposed to be one such mechanism. Indeed, animals with mutations
of these pathways, including insulin-like growth factor / insulin and mammalian target of
rapamycin (mTOR) pathways, have increased lifespan. For example, mice with deletion
of ribosomal S6 protein kinase 1 have extended lifespan and have gene expression
patterns similar to that of caloric-restricted animals [299]. Adipose-specific insulin
receptor knockout mice also have lower adiposity and extended lifespan [300].
Prevention of age-related deterioration of insulin sensitivity is another mechanism
proposed to mediate effects of caloric-restriction on longevity. Growth hormone activity
is known to be associated with insulin resistance, and growth-hormone receptor knockout
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(GHRKO) mice are insulin sensitive and have a prolonged lifespan. Because caloricrestriction does not have additional effects on longevity on these mice, it is likely that GH
also mediates effects of caloric-restriction on longevity.
Finally, the beneficial effects of caloric restriction in animals are at least in part
mediated via the histone deacetylases sirtuins [301]. Mammalian sirtuins include SIRT17. SIRT1 is upregulated in caloric restriction and promotes fatty acid oxidation in the
liver and skeletal muscle and improves glucose homeostasis [302]. Further, SIRT1
activators, such as resveratrol extend lifespan in organisms such as yeast [303]. SIRT2 is
also upregulated in adipose tissue following caloric restriction [304], while SIRT3 is
mainly expressed in mitochondria and regulates fatty acid metabolism [305].
While the aforementioned mechanisms are responsible for the beneficial effects
of caloric restriction on longevity, it is not evident whether similar mechanisms operate in
obese animals as well. Limited evidence suggests that SIRT1 activation protects from
high-fat diet-induced metabolic derangements. For example, resveratrol prevents the
development of insulin resistance in high-fat fed mice [306]. Although these sirtuins are
implicated in mediating the beneficial roles of caloric restriction, whether these
mechanisms operate in obese humans subjected to caloric restriction remains to be
elucidated.

Macronutrient composition of a caloric restricted diet
Most health agencies recommend a low-fat diet for weight loss and improvement
of metabolic health. However, low-carbohydrate, high-fat reduced-energy diets are also
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effective in weight loss [307]. While energy restriction, rather than macronutrient
composition, seems to be more important for improving insulin sensitivity [308], the
effects of these high-fat reduced-energy diets on other cardiovascular risk factors are not
well known. In contrast, low-fat diets are known to reverse coronary artery disease [309]
and reduce cardiovascular disease risk factors such as low-density lipoprotein cholesterol
levels [310]. Therefore, it is important to study the effects of energy-restricted diets with
varying macronutrient compositions on metabolic markers. It is especially crucial to
dissect the role of dietary fat in health and disease, due to its higher energy density.

Effect of macronutrient composition on degree of weight loss and insulin sensitivity
Caloric restriction, rather than macronutrient composition, appears to be more
important for weight loss. Low-fat, low-carbohydrate, very-low carbohydrate and highprotein diets induce similar degrees of weight loss [311]. Although very lowcarbohydrate ketogenic diets induce greater weight loss short-term, this difference is not
significant after 1 year [310].
Caloric restriction leading to weight loss also seems to be more important for
improvements in insulin sensitivity, than the macronutrient composition of the diet. In a
large randomized controlled trial, lower intakes of dietary fat reduced the risk of type-2
diabetes only in the presence of weight loss [312]. However, animal studies show that
very low-carbohydrate diets induce hepatic lipid accumulation and might not improve HF
diet-induced insulin resistance to the same extent as high-carbohydrate low-fat diets [313,
314].
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Effect of macronutrient composition on serum cholesterol levels
In addition to weight loss and improvement in insulin sensitivity, low-fat diets
also reduce circulating total cholesterol and low-density lipoprotein (LDL) cholesterol
levels. However, they have an undesirable effect of lowering high-density lipoprotein
(HDL) cholesterol level as well. In contrast, low-carbohydrate diets reduce triglyceride
and very low-density lipoprotein (VLDL) cholesterol levels, with a slight increase in
LDL cholesterol levels [310, 315]. These low-carbohydrate diets also induce a greater
degree of reduction in the total/HDL cholesterol ratio [235].

Effect of macronutrient composition on adipose tissue function
Caloric restriction alters lipolytic rates and lipogenesis in adipose tissue
(discussed above). However, the fat/carbohydrate content of a caloric restricted diet does
not change insulin-stimulated glucose transport or lipolysis in human subcutaneous
adipose tissue [316].
Only a few studies have investigated the effect of macronutrient composition of a
caloric-restricted diet on adipose tissue gene expression. In one study, dietary energy
intake was restricted by 600 kcal/day in obese women by either a low-fat (20-25% of
total energy by fat) or a moderate-fat (40-45% of total energy by fat) diet [246]. During
10 weeks of the intervention, body weight of women in both groups decreased an average
of 7.5%. In the subcutaneous adipose tissue, mRNA expression of leptin and IL-6 were
reduced by both diets, with no changes in TNF-α, PAI-1, IL-8 and adiponectin
expression. When the protein secretion was considered, leptin, IL-6 and IL-8 were
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reduced by both diets, while TNF-α reduced only by the low-fat diet. This shows that
during caloric restriction, the effect of macronutrient composition is minimal. In another
study, microarray analysis of adipose tissue of obese women showed that a majority of
genes were differentially expressed in response to caloric restriction, but only a few genes
responded to the fat / carbohydrate content of the diet [315]. These latter genes included
FABP4, SIRT3, NR3C1, FNTA, and GABARAPL2, which were expressed at higher levels
in the low-carbohydrate group.
In conclusion, caloric restriction, regardless of the macronutrient composition of
the diet, induces weight loss and improves systemic insulin sensitivity. However, the
effect of macronutrient composition in reduced-energy diets on adipose tissue function
and other cardiovascular risk factors need further characterization.

Long-chain (n-3) polyunsaturated fatty acids for improvement of insulin resistance
and metabolic derangements in obesity

Disclosure: The work described in this section has been submitted for the following
publication, with minor modifications in the numbering of tables and figures:
“Kalupahana NS, Claycombe KJ and Moustaid-Moussa N. (n-3) fatty acids alleviate
adipose tissue inflammation and insulin resistance: mechanistic insights. Advances in
Nutrition in press, 2011”
While caloric restriction leading to weight loss is a successful dietary intervention
for improving obesity-associated metabolic disorders, other dietary interventions such as
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ones targeted at reducing adipose tissue inflammation, regardless of weight loss, have not
been explored in detail. Long-chain (n-3) polyunsaturated fatty acids of marine origin
[(n-3) LC-PUFA] namely eicosapentaenoic acid [20:5 (n-3), EPA] and docosahexaenoic
acid [22:6 (n-3), DHA] have known anti-inflammatory properties [317]. Moreover, they
reduce plasma triglycerides, reduce cardiac events and delay the progression of
atherosclerosis [318, 319]. They also have anti-obesity effects on humans [320] and
rodents [321].
In contrast, the effect of EPA/DHA on insulin sensitivity is not well characterized.
While EPA/DHA consistently prevent the development of insulin resistance associated
with high-fat [322, 323] or high-sucrose [324] feeding in rodents, they do not improve
insulin sensitivity in individuals with type-2 diabetes [325, 326]. However, preliminary
evidence suggests that EPA/DHA might help delay the progression of metabolic
syndrome to type-2 diabetes [327]. In this context, elucidating the mechanisms
responsible for improvement of insulin sensitivity due to EPA/DHA might enhance the
understanding of the pathophysiology of obesity-associated insulin resistance and could
potentially lead to discovery of novel therapeutic targets for the metabolic syndrome.

(n-3) and (n-6) polyunsaturated fatty acids
(n-3) and (n-6) polyunsaturated fatty acids are the two main classes of essential
fatty acids. In (n-3) fatty acids, the first double bond is located between the 3rd and 4th
carbons counting from the methyl end (Figures 6 and 7), while in (n-6) fatty acids this is
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Figure 6. Structures of main (n-3) and (n-6) polyunsaturated fatty acids
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Figure 7. Metabolism of (n-3) and (n-6) fatty acids
Linoleic (LA) and α-linolenic acid (ALA) are the parent (n-6) and (n-3) long-chain
polyunsaturated fatty acids. LA is converted to arachidonic acid (AA), while ALA is
converted to eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). AA-derived
eicosanoids are pro-inflammatory, while EPA-derived ones are less so. EPA and DHA
metabolites such as resolvins and protectins have important roles in resolution of
inflammation.
COX – cyclooxygenase
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located between the 6th and 7th carbons from that end. These are considered essential
fatty acids because humans cannot synthesize them due to absence of delta-12 and 15
desaturase enzymes. Linoleic acid (LA) is the parent long-chain (n-6) fatty acid, which
can be converted into arachidonic acid (AA) (Figure 7). LA is found mainly in vegetable
oils such as corn, sunflower and soybean oil, while AA is found in foods of animal origin
such as meat and egg-yolk [328]. α-linolenic acid (ALA), is the parent (n-3) fatty acid,
which can be converted to EPA and DHA. ALA is found in nuts such as walnuts and flax
seed, while EPA and DHA are found primarily in foods of marine origin such as oily fish.
AA-derived eicosanoids such as PGE2 and thromboxane A2 are pro-inflammatory, while
EPA-derived ones such as PGE3 are less inflammatory. EPA and DHA are also
metabolized into resolvins and protectins, which have important roles in resolution of
inflammation (Figure 7).
The ratio of (n-6) /(n-3) polyunsaturated fatty acids in the western diet ranges
from about 10/1 to 20/1 [329]. In countries with a relatively higher fish consumption such
as Japan, this ratio is 4/1 [330]. Dietary intake of these fatty acids affects the proportion
of AA/EPA ratio in phospholipids, which affects cardiovascular disease risk [331]. The
(n-3) index is a measure of erythrocyte EPA+DHA to total fatty acid ratio, which has
been proposed to be used as a cardiovascular disease risk factor. Individuals with a low
(n-3) index have a higher risk of cardiac events [332]

EPA/DHA and hepatic insulin sensitivity
The effect of (n-3) LC-PUFA, mainly EPA, on lowering plasma triglycerides is
well established. This effect is at least in part due to their ability to inhibit hepatic
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enzyme diacylglycerol acyltransferase (DGAT) [333], which catalyses the final reaction
of triglyceride synthesis. In addition to this triglyceride lowering effect, EPA/DHA also
prevents the development of hepatic steatosis [334] and insulin resistance [323]
associated with high saturated fat (HF) feeding in rodents.
Lipid accumulation in the liver depends on non-esterified fatty acid delivery to the
liver, de novo lipogenesis and the rate of fatty acid oxidation. In obesity, there is a net
increase in fatty acid availability, promoting lipid deposition in the liver. Moreover,
lipogenic gene transcription factors such as sterol regulatory element-binding protein
(SREBP)-1c, are expressed at a higher level in obesity [335]. This leads to increased
expression of hepatic lipogenic genes such as fatty acid synthase (FAS) and stearoyl-CoA
desaturase 1 (SCD1) [336]. Further, obesity is also associated with suppression of
peroxisome proliferator-activated receptor (PPAR)-α [335] leading to reduced fatty acid
oxidation [336]. All these processes are linked to the development of hepatic steatosis.
Excessive lipid accumulation in the liver leads to hepatic insulin resistance and blunting
of insulin-mediated suppression of hepatic glucose production.
EPA reduces lipogenesis and increases fatty acid oxidation [337], preventing lipid
accumulation in the liver, leading to improvements in hepatic insulin resistance (Figure
8). Moreover, EPA reduces lipogenesis via inhibition of lipogenic transcription factors
such as SREBP-1c, nuclear factor-Y [338] and carbohydrate-responsive element-binding
protein (ChREBP) [339]. EPA stimulates fatty acid oxidation via activation of PPARα
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Figure 8. Effect of EPA/DHA on liver, skeletal muscle and adipose tissue metabolism
EPA/ DHA promote hepatic fatty acid oxidation and suppress lipogenesis. This leads to
reduced accumulation of TAG in the liver. These fatty acids also increase adipose tissue
fatty acid oxidation and increase secretion of adiponectin, leptin and visfatin. EPA/DHA
also alleviate adipose tissue inflammation via GPR120 and resolvins / protectins. In the
skeletal muscle, EPA/DHA promote fatty acid oxidation, thereby preventing
accumulation of fatty acid intermediates. All these mechanisms are responsible for the
EPA/DHA- mediated improvement in insulin sensitivity. FA – fatty acids, DAG –
diacylglycerol, TAG – triacylglycerol, DGAT – diacylglycerol acyl transferase.
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[336, 340-342] and AMP-activated protein kinase (AMPK) [343]. PPARα is required for
EPA’s beneficial effects on hepatic insulin sensitivity, as evident by a lack of EPA effect
in restoring hepatic insulin sensitivity in PPARα null mice fed a HF diet [344].
Interestingly, these mice continue to exhibit low plasma triglyceride levels, concomitant
with diacyl glycerol accumulation in the liver, suggesting that EPA exerts a PPARαindependent effect on hepatic DGAT. AMPKα2 is another signaling enzyme,coordinately
regulated with PPARα during fat oxidation. As expected, and in line with the PPARα null
mice phenotype, AMPKα2 null mice do not exhibit EPA’s beneficial effects on
improvement in hepatic insulin sensitivity [345].

Effects of EPA/ DHA on adipose tissue function
EPA/DHA reduce adiposity in humans [346] especially when combined with
caloric restriction [320]. These fatty acids also prevent the development of high-fat diet
induced adiposity and adipocyte hypertrophy in rodents [347]. There are two possible
mechanisms for these anti-obesity effects of EPA/DHA. First, EPA/DHA is known to
increase fatty acid oxidation in liver, adipose tissue [348] and small intestine [349] in
vivo and adipocytes [350] and myotubules [351] in vitro. Second, they are known to
inhibit hepatic lipogenesis (Figure 8). Both these processes shift the balance of fatty acid
metabolism toward oxidation, rather than storage. EPA/DHA activate AMPK in adipose
tissue and cultured adipocytes, which could be a mechanism for their effect on fatty acid
oxidation [352, 353]. Further, these PUFAs are also known to induce mitochondrial
biogenesis [318].
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While it is possible that improvements of systemic insulin resistance due to
EPA/DHA are secondary to reduction in adipose mass, this could also be due to direct
actions of these fatty acids in improving adipose tissue function. Indeed, some studies
have shown that these (n-3) LC-PUFA-mediated insulin sensitivity is preserved even in
the presence of increased adipose mass [354].
EPA/DHA modulate adipokine secretion from adipose tissue (Figure 8). They
increase plasma adiponectin levels in obese humans [355, 356] and rodents [357], which
could be a potential mechanism by which EPA/DHA improve insulin sensitivity. This
effect of EPA/DHA on adiponectin is PPARγ-dependent, because adiponectin is not
elevated in response to fish oil in mice lacking PPARγ [358]. They also induce leptin and
visfatin secretion and reduce the expression of several proinflammatory cytokines from
the adipose tissue including TNFα and IL-6 [359-361]. Current evidence suggests that
these anti-inflammatory actions of EPA/DHA play a major role in their insulinsensitizing effects.
Adipose tissue macrophage infiltration and phenotypic switch is causally linked to
insulin resistance in obesity (discussed previously). EPA/DHA prevent HF diet-induced
adipose tissue macrophage infiltration in mice [362]. Production of pro-inflammatory
cytokines by macrophages is dependent on activation of the NF-kB and JNK pathways.
EPA/DHA bind to G protein-coupled receptor 120 (GPR120) and inhibit NF-kB and
JNK, attenuating this response [363]. The importance of this receptor is highlighted by
the finding that the EPA-mediated improvement in insulin sensitivity is absent in mice
lacking GPR120. Another G protein-coupled receptor, GPR40 is also known to be
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activated by long-chain PUFA [364]. Recent evidence has highlighted the role of
EPA/DHA in resolving inflammation, through mechanisms involving EPA-derived
resolvin E1 and DHA-derived protectin D1 [365]. In HF-fed mice, protectin D1 is
lacking in the adipose tissue and skeletal muscle. Moreover, transgenic restoration of (n3) PUFA and protectin D1 prevents the HF diet-induced insulin resistance, highlighting
the important role of this DHA-derivative [366].

EPA/DHA and skeletal muscle metabolism
Triglyceride accumulation in skeletal muscle fibers has been linked to insulin
resistance (discussed previously). Proposed mediators include increased fatty acid
availability and impaired fatty acid oxidation in the skeletal muscle. The latter is also
associated with accumulation of fatty acid intermediates such as diacylglycerol and
ceramides. Exposure of myotubules to EPA enhances glucose uptake [367], indicating
increased insulin sensitivity. EPA also protects from the development of HF-induced
skeletal muscle insulin resistance in vivo [368]. Interestingly, EPA increases both TAG
accumulation and fatty acid β oxidation (Figure 8) while improving skeletal muscle
insulin sensitivity both in vitro [351] and in vivo [369].
Because EPA/DHA also reduce skeletal muscle ceramide content [357], it is
possible that their effect on maintaining skeletal muscle insulin sensitivity is related to
their ability to normalize fatty acid oxidation with lower accumulation of fatty acid
intermediates. Saturated fatty acids induce skeletal muscle insulin resistance via
activation of the NF-kB pathway [370]. Since EPA/DHA inhibit this pathway in other
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tissues, it will be interesting to determine whether EPA/DHA inhibit this pathway in the
skeletal muscle, and subsequently prevent the saturated fatty acid-mediated insulin
resistance.
In summary, EPA/DHA prevent excessive adiposity and insulin resistance in
rodents. Mechanistically, this is related to the ability of these fatty acids to increase
hepatic, skeletal muscle and adipose tissue fatty acid oxidation and their ability to reduce
lipogenesis. EPA/DHA also have important anti-inflammatory properties which modulate
adipose tissue inflammation via GPR120-mediated suppression of macrophage proinflammatory cytokine secretion, resolvin and protectin-mediated resolution of
inflammation. Through modulation of adipokine secretion, these fatty acids also favor
insulin sensitivity. Most studies have addressed preventive effects of these PUFA,
however whether these macronutrients are also able to reverse insulin resistance in
obesity or their mechanisms for modulating adipocyte secretory function needs further
characterization.
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Goal and specific aims
The overarching goal of this dissertation research is elucidating adipose tissue function in
metabolic syndrome using genetic and nutritional manipulations/approaches, with
specific emphasis on the roles of inflammation and angiotensinogen.

Specific Aims
I. Determine the role of adipose tissue angiotensinogen (Agt) overexpression in the
pathogenesis of insulin resistance in obesity
In this specific aim, we test the hypothesis that overexpression of Agt from adipose tissue
induces systemic insulin resistance via NADPH oxidase and NF-kB-dependent increases
in adipose tissue inflammation (Figure 9). We have the following objectives.
A. Determine the metabolic and adipose tissue gene expression changes resulting
from overexpression of Agt in adipose tissue.
B. Determine the metabolic changes resulting from high-fat feeding in mice with
overexpression of Agt in adipose tissue in the presence and absence of ACE
inhibitor captopril.
C. Determine whether the effects of adipose Agt overproduction on adipokine
secretory patterns in murine adipocytes are mediated via NADPH oxidase and
NF-kB
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Figure 9. Hypothesis for specific aim I
We propose that overproduction of Agt from adipose tissue leads to increased lipogenesis
and activation of NADPH oxidase, which in turn lead to activation of the NF-kB pathway
in adipocytes. This will increase transcription of pro-inflammatory adipokines and
suppress the anti-inflammatory adipokines leading to systemic insulin resistance.
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II. Determine the role of energy-restricted high-fat diets in reversing metabolic
derangements of obesity
In this specific aim, we test the hypothesis that weight loss due to an energy-restricted
high-fat diet is accompanied by improvements in insulin sensitivity, adipose tissue
inflammation and metabolic markers (Figure 10). To test this hypothesis, we have the
following objective.
A. Determine the changes in metabolic markers and adipose tissue gene expression
patterns in mice fed a low-fat, high-fat or a high-fat energy-restricted diet

III. Elucidate mechanisms of (n-3) polyunsaturated fatty acid-mediated prevention
and reversal of insulin resistance in high-fat diet-induced obesity
In this specific aim we test the hypothesis that eicosapentaenoic acid (EPA) would
prevent and reverse the metabolic derangements occurring in diet-induced obesity (DIO)
via modulation of adipose tissue inflammation (Figure 10). We have the following
objectives.
A. Determine metabolic alterations in adipose tissue and changes in glucose
tolerance, insulin sensitivity and circulating metabolic biomarkers in mice fed a
low-fat, high-fat or a high-fat EPA diet
B. Determine mechanisms by which EPA modulates HF diet-induced adipose tissue
inflammation
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Figure 10. Hypotheses for specific aims II and III
Obesity leads to adipocyte hypertrophy and a dysregulation of adipokine secretion
favoring inflammation. We propose that loss of adiposity due to energy-restricted highfat diets will also lead to improvements in adipokine secretory patterns and metabolic
markers. We also propose that EPA would modulate adipose tissue inflammation and
thereby improve systemic insulin resistance induced by high-fat feeding.
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CHAPTER III
ROLE OF ADIPOSE TISSUE ANGIOTENSINOGEN (AGT) OVEREXPRESSION
IN THE PATHOGENESIS OF INSULIN RESISTANCE IN OBESITY

Disclosure: The work described in this chapter in its entirety has been submitted for the
following publication, with minor modifications in the numbering of tables and figures:
“Kalupahana NS, Massiera F, Quignard-Boulange A, Ailhaud G, Voy BH, Wasserman
DH and Moustaid-Moussa N. Overproduction of angiotensinogen from adipose tissue
induces adipose tissue inflammation, glucose intolerance and insulin resistance.
Submitted to Endocrinology”

Introduction
The renin-angiotensin system (RAS) is classically known for its role in the
regulation of blood pressure and fluid balance [371]. Angiotensinogen (Agt) is cleaved
by the enzymes renin and angiotensin-converting enzyme (ACE) successively, to form
angiotensin II (Ang II), the main bioactive peptide of this system. In addition to Ang II,
several other angiotensin peptides such as Ang 1-7 are also generated by the RAS [372].
It is also well documented that other non classical enzymatic and non enzymatic
pathways can generate many of the RAS intermediate peptides [371]. Ang II exerts its
physiological actions, primarily via two G-protein coupled receptors, Ang II Type 1
(AT1) and Type 2 (AT2) receptors [371]. Hence, ACE inhibitors and angiotensin receptor
blockers (ARBs) are common drug targets for anti-hypertensive therapy [371].
Interestingly, several clinical trials have shown that the risk for type-2 diabetes mellitus is
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lower in hypertensive individuals treated with ACE inhibitors or ARBs compared to
those treated with other anti-hypertensive medications [373]. Subsequent randomized
controlled trials have also shown that RAS blockade improves glucose tolerance and
insulin sensitivity in previously insulin resistant individuals [374]. Further, RAS blockade
also ameliorates insulin resistance and glucose intolerance in several rodent models of
obesity [188, 375]. However, the exact mechanism of modulation of insulin sensitivity
via RAS blockade is not fully understood.
Adipose tissue is well recognized now as an important endocrine organ which
secretes a number of bioactive peptides collectively known as adipokines. These include
leptin, adiponectin, resistin, tumor necrosis factor-α (TNF-α), plasminogen activator
inhibitor-1(PAI-1), monocyte chemotactic protein-1(MCP-1) and Ang II [23]. Obesity
leads to a chronic low-grade inflammatory state in the adipose tissue and a dysregulation
of adipokine secretory patterns, which is causally linked to the pathogenesis of metabolic
syndrome and Type-2 diabetes [376]. Several lines of evidence point to the adipose RAS
as a potential link between obesity and insulin resistance. Indeed, adipose tissue
synthesizes and secretes the major components of RAS [377]. There is also evidence for
overactivation of adipose tissue RAS in obesity in rodents [143, 152], and for a positive
correlation between adipose tissue Agt levels and body mass index in humans [52].
Moreover, circulating levels of Agt correlate with BMI and estimated total adipose
tissue-derived Agt in humans [123], suggesting an endocrine role for adipose Agt.
Further, Ang II secretion from adipose tissue is increased following sympathetic
stimulation in obese, but not lean, individuals [129]. Conversely, plasma and adipose Agt
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levels are decreased following weight-loss [130]. Despite this strong evidence for an
association between adipose RAS overactivation and insulin resistance, it is hitherto
unknown whether the former is causally linked to the latter.
More recent studies targeted manipulation of RAS (overexpression or deletion)
and subsequent effects on obesity and insulin sensitivity. Loss of function in any single
component of the RAS tested so far, provides protection from diet-induced obesity and
insulin resistance; i.e. Agt, Renin, ACE, AT1 or AT2 knockout rodents are lean and
insulin sensitive [173-175, 178, 378]. Systemic RAS overactivation via gene
overexpression or chronic Ang II infusion also induces insulin resistance, but not
necessarily obesity [159, 197, 202]. Considering the relationship of adipose tissue
inflammation to insulin resistance, it is possible that overactivation of adipose RAS
specifically, leads to obesity and associated insulin resistance and inflammation. The
hypothesis that adipose RAS overactivation will induce insulin resistance via increasing
adipose tissue inflammation was tested in the present studies using a mouse model which
overexpresses Agt in adipose tissue via the adipose aP2 promoter (aP2-Agt mice). These
mice have elevated plasma Agt and develop hypertension [157]. As previously reported,
male aP2-Agt mice exhibit higher fat pad weights compared to wild type littermates.
Here, we further demonstrate that these mice also develop adipose tissue inflammation,
glucose intolerance and insulin resistance even on a low-fat diet. Moreover, the glucose
intolerance was significantly improved when aP2-Agt mice were treated with ACE
inhibitor, captopril. Our studies thus demonstrate that adipose tissue RAS overactivation
causes systemic insulin resistance in an Ang II-dependent manner.
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Research Design and Methods
Animals
Generation of transgenic mice overexpressing Agt in adipose tissue using the
adipose aP2 promoter (aP2-Agt mice) has been described previously [157]. Mice used in
the current study were bred on a C57BL/6J background and maintained in our animal
facility at the University of Tennessee. Genotyping of the offspring was performed using
PCR of genomic DNA using transgene-specific (5’-CTTTGCCTTTCTCTCCACAG-3')
and intron-specific (5'-TTATCTCGCAGGGTCTTCTC-3') oligonucleotides. All mice
were housed under 12-hour light/dark cycles with free access to food and water. For the
first study, mice were fed a regular low-fat (LF) diet from weaning. For the second study,
a separate cohort of male mice were fed a high-fat (HF) diet (45, 20, and 35% of energy
from fat, protein, and carbohydrate, respectively; D12451 Research Diets, New
Brunswick, NJ)) [379] for 12 weeks from the time of weaning. The mice on the HF diet
were housed individually. Half the number of HF-fed mice was given the ACE inhibitor
captopril with drinking water (30mg/L). At the end of each study, mice were feeddeprived for 6 hours and then killed using the CO2 inhalation method. Blood was
collected into tubes with EDTA, kept on ice for 10 min, centrifuged at 3000 X g for 20
min, and plasma samples were collected and stored at -800C for subsequent analyses.
Gonadal (epididymal or periovarian), inguinal, retroperitoneal and subscapular fat pads
were dissected, snap-frozen in liquid N2, and stored at -800C for subsequent analyses.
These protocols were all approved by the Institutional Animal Care and Use Committee
of the University of Tennessee, Knoxville.
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Glucose tolerance test
Mice were feed-deprived for 6 hours with free access to water. A drop of tail
blood was used to measure the blood glucose levels using the One Touch Ultra
glucometer. Next, 1 g/kg body weight of 20% D-glucose was injected intraperitoneally.
Serial blood glucose measures were taken at 15, 30, 60, and 120 min after the injection.

Hyperinsulinemic, euglycemic clamp
Detailed procedure has been previously reported [380].

Catheters were

chronically implanted in the jugular vein (for infusions) and carotid artery (for sampling)
5 to 7 days prior to clamps (n=8-10). Insulin was continuously administered at 4
mU/kg/min. Arterial glucose levels were measured every 5-10 min and glucose infusion
rates were adjusted to maintain fasting glucose. Mice were infused with [3-3H]glucose at
a rate of 0.4 µCi/min. Endogenous glucose appearance (Ra) and disappearance (Rd) rates
were calculated as described previously [380]. Glucose clearance was calculated by
dividing the Rd by the arterial glucose concentration. To measure a tissue-specific index
of glucose metabolism (Rg), mice were injected with 12 µCi of [3H]-labeled 2deoxyglucose ([2-3H]DG). Arterial plasma samples were collected in intervals for 40
minutes before mice were anesthetized and tissues were extracted and frozen in liquid
nitrogen until further analysis.
Plasma analyte measurements
Commercially available ELISA kits were used to measure plasma Agt, leptin and
total adiponectin (Linco Research, Billerica, MA) concentrations, whereas a colorimetric
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assay was used to measure plasma nonesterified fatty acids (Wako Chemicals USA,
Richmond, VA). Plasma insulin, monocyte chemotactic protein-1 (MCP-1) and resistin
concentrations were measured using a commercially available microsphere-based
multiplexing system (Luminex xMAP, Millipore, Billerica, MA).

Adipose tissue adipokine measurements
Because the epididymal (gonadal) fat depot is known to show a pronounced
dysregulation of adipo/cytokine secretory patterns in response to high-fat diets and other
metabolic challenges [381], we used it to study the adipo/cytokine changes in our mice.
Epididymal adipose tissue was homogenized in modified radio-immunoprecipitation
assay buffer containing a cocktail of protease inhibitors for total protein extraction. The
protein concentration was determined by the Bradford assay (18). Luminex xMAP was
used to measure adipokines. Analyte values in the adipose protein extracts were
normalized to total protein concentration.

Proteomics
Proteins were extracted from epididymal adipose tissue of aP2-Agt and control
littermates matched for adipose mass, and labeled with cyanine 3 or 5 (green or red),
respectively. Both samples were run on a 2-dimensional gel electrophoresis (Applied
Biomics). A complete analysis of all differentially expressed proteins was obtained using
Decyder software from which quantitative data were derived. Spots with a volume ratio
of >30% and a consistent presence in replicate gels were identified and obtained using the
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spot picker robot, and proteins within each spot were enzymatically digested and
analyzed by Mass Spectrometry. Proteins identified from this analysis were then
uploaded into DAVID Bioinformatics Resources, where the functional annotation chart
was used to search for significantly enriched gene ontology categories. Differential
expression of these proteins was further confirmed by western blotting.

Cell culture experiments
Adipocytes were cultured as described previously [382]. Briefly, 3T3-L1
preadipocytes were cultured in 6-well plates in regular growth media consisting of
Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% fetal bovine
serum and 1% penicillin/streptomycin (P/S). At confluence, the cells were differentiated
by the addition of growth media supplemented with 250 nmol/L dexamethasone and 0.5
mmol/L methyl isobutylxanthine for 72 h, after which regular media were added for 2
additional days. Subsequently, cells were placed in serum-free media [DMEM, P/S, and
1% bovine serum albumin (BSA)] for 18 hours prior to applying various treatments for
24 hours, as described in the results and figure legends. Secreted adipokine levels were
assayed in culture media, using Luminex Xmap.

Western immunoblotting
Total proteins were isolated from epididymal adipose tissue, homogenized in
modified RIPA buffer containing a cocktail of protease inhibitors. Twenty micrograms of
total protein was loaded into each lane and separated by electrophoresis in an 8–10%
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polyacrylamide gel. Proteins were transferred to a nitrocellulose membrane in transfer
buffer, blocked overnight with 5% non-fat dry milk in Tris-buffered saline, and 0.1%
Tween, incubated with polyclonal antibodies against monoglyceride lipase (MGL) and
actin (Santa Cruz Biotechnology, Santa Cruz, CA), followed by secondary antibodies
containing horseradish peroxidase and finally detected by chemiluminescence.

Statistical analysis
Body and fat-pad weight, area under the glucose curve (AUC) and plasma
biomarkers were analyzed by ANOVA using the general linear models procedure, taking
the effect of the genotype, sex, and interactions between these factors into account. For
the diet study, a similar analysis was performed taking the effect of genotype, treatment
and interactions between these factors into account. Glucose infusion rate and tissue
glucose uptake in the clamp studies, adipose tissue cytokine levels and MGLL expression
was compared using the student t test. In the cell culture studies, one way-ANOVA was
used. If the F test was significant, group means were compared using the Tukey’s post
hoc test for multiple comparisons. The fold difference in protein expression between
replicate gels in proteomic studies was compared using the 1-sample t test. The level of
significance for all tests was P < 0.05. All data are expressed as mean ± SD.
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Results
Adipose Agt overexpression induces higher adiposity, glucose intolerance and
insulin resistance
As expected, the aP2-Agt transgenic mice had higher adipose Agt levels (5.2 ±
3.9, 16.9 ± 8.6, 15.9 ± 7.7 and 20.4 ± 10.8 μg/g protein in female wild-type (Wt), female
transgenic, male Wt and male transgenic respectively; p < 0.05 for genotype effect) at the
age of 24-weeks. Similar to previous reports [157], the transgenics also had
approximately 20% higher plasma Agt levels (Table 5) than the Wt mice. These mice
also exhibited higher fat pad weights, while there was no genotype effect on body weight
(Figure 11A and B). An intra-peritoneal glucose tolerance test performed at 22-weeks of
age showed that male transgenics were glucose intolerant as compared to Wt males,
indicated by a higher area under the glucose curve (AUC -Figure 11C and D). However,
this difference in glucose tolerance was not seen in female mice.
While the transgenics also had higher plasma leptin levels compared to their Wt
counterparts, as expected from fat pad weight differences, there was no significant
genotype effect on plasma levels of several other adipocytokines (Table 5). Next, to
determine if overexpression of Agt in adipose tissue causes insulin resistance, we
performed hyperinsulinemic, euglycemic clamps on male aP2-Agt mice. The transgenics
had a lower steady-state glucose infusion rate compared to Wt mice, indicating lower
insulin sensitivity (Figure 12B, C). The difference in glucose clearance between basal and
clamp was also lower in the transgenics (Figure 12D). Isotope studies for tissue glucose
uptake showed that Rg was significantly lower in the gastrocnemius and vastus muscles
71

Table 5. Plasma biomarkers in low-fat fed aP2-agt mice#

Females
Wt

Insulin
(pmol/L)
Glucose
(mg/dL)
Adiponectin
(mg/L)
Leptin
(μg/L)
Agt (mg/L)
NEFA
(mmol/L)
MCP-1
(ng/L)
Resistin
(ng/L)

Males
Tg

Wt

Tg

Sex
effect

P Value
Genotype Sex X
Effect
Genotype
Effect

131 ± 93

164 ± 67

191 ± 73

312 ± 133

0.019*

0.157

0.725

204 ± 16

183 ± 9

199 ± 15

221 ± 22

0.352

0.753

0.166

18.2 ± 7.0

19.7 ± 6.1

9.8 ± 3.1

9.9 ± 2.9

0.001*

0.743

0.769

1.6 ± 1.0

4.1 ± 2.5

2.9 ± 1.7

6.0 ± 4.6

0.204

0.046*

0.508

2.8 ± 0.8

3.4 ± 0.8

3.4 ± 0.5

4.4 ± 0.4

0.021*

0.022*

0.617

0.55 ± 0.19

0.70 ± 0.19

0.62 ± 0.22

0.71 ± 0.19

0.649

0.200

0.727

18.9 ± 7.0

25.4 ± 15.0

22.6 ± 14.7

24.0 ± 9.2

0.894

0.638

0.761

1400 ± 211

1748 ± 566

1184 ± 279

1032 ± 99

0.034*

0.777

0.267

#

Data is presented as mean ± SD (n=4-9 per group); Wt – wild-type, Tg - transgenic
* p < 0.05
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Figure 11. Adipose Agt overexpression induces adiposity and glucose intolerance
Wild-type (Wt) and transgenic (Tg) aP2-Agt mice were fed a low-fat diet from weaning
until 24-weeks of age. Body weight (A) and fat pad weight (B) are shown. At 22-weeks
of age, an intraperitoneal glucose tolerance test was performed. Change in blood glucose
over time (C) and area under the glucose curve (AUC) (D) are shown. Data are presented
as mean ± SEM (n=4-9 per each group). # p <0.05 for sex effect; * p < 0.05 for genotype
effect.
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Figure 12. Adipose Agt overproduction induces insulin resistance
Low-fat diet fed, male aP2-Agt wild-type (Wt) and transgenic (Tg) mice were subjected
to a hyperinsulinemic, euglycemic clamp. Change in blood glucose (A) and glucose
infusion rate (B) over time, mean steady-state glucose infusion rate (C) and glucose
clearance rate (D) are shown. Using [3H]-labeled 2-deoxyglucose, tissue-specific index of
glucose metabolism (Rg) was measured (E). Data are presented as mean ± SEM (n=8-10
in each group). * p < 0.05
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in the transgenic mice compared to the Wt mice (Figure 12E). Interestingly, the
transgenics also had lower cardiac Rg. While there was a trend for an increase in adipose
tissue Rg (adjusted for adipocyte number) of transgenics, this was not significant.

Captopril attenuates glucose intolerance in HF-fed aP2-Agt and Wt mice
HF feeding is known to induce glucose intolerance and insulin resistance in
C57BL/6J mice [77]. To test that adipose RAS overactivation exacerbates HF dietinduced glucose intolerance, we fed transgenic and Wt litermates a HF diet for 12 weeks.
To determine if the glucose intolerance was Ang II-dependent, we also treated a cohort of
HF-fed mice with the ACE inhibitor, captopril (30mg/L in drinking water). In contrast to
males on the LF diet (figure 11D), the glucose tolerance was similar in both transgenics
and Wt mice on the HF diet, as indicated by similar AUCs (Figure 13C and D). Captopril
prevented the HF-diet induced increase in adiposity (Figure 13A and B) and glucose
intolerance in both transgenic and Wt mice (Figure 13C and D). Thus, while aP2-Agt
mice exhibited glucose intolerance compared to control littermates when fed low-fat
diets, HF feeding normalized these difference in glucose tolerance between genotypes.
Further, ACE inhibition improved HF diet-induced glucose intolerance in both
genotypes.
Adipose Agt overexpression increases markers of adipose inflammation
Chronic low-grade inflammation in adipose tissue is causally linked to the
pathogenesis of insulin resistance in obesity. To determine if adipose inflammation is a
potential mechanism for the insulin resistance in aP2-Agt mice, we measured selected
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Figure 13. Captopril attenuates high-fat diet induced adiposity and glucose intolerance
Male aP2-Agt wild-type (Wt) and transgenic (Tg) mice were fed a high-fat diet (45, 20,
and 35% of energy from fat, protein, and carbohydrate, respectively) for 11 weeks. Half
of each genotype was given captopril (cap - 30mg/L) in drinking water. Body weight (A)
and fat pad weight (B) are shown. At 10 weeks on the high-fat diet, an intra-peritoneal
glucose tolerance test was performed. Change in blood glucose concentration over time
(C) and area under the glucose curve (AUC) (D) are shown. Data are presented as mean ±
SEM (n=8-12 in each group). * p <0.05 treatment effect.
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markers of adipose inflammation. Pro-inflammatory cytokine MCP-1 was nearly twofold higher in the epididymal adipose tissue of the transgenics compared to Wt litermates
(Figure 14). Further, expression of interleukin-10 (IL-10), an anti-inflammatory cytokine
was significantly lower in the transgenics. The hematopoietic cytokine IL-7 and
leukocytotrophic cytokine IL-2 were expressed lower in the transgenics. These findings
indicate that adipose Agt overexpression induces adipose tissue inflammation.

Angiotensin II increases secretion of MCP-1 and resistin in adipocytes
Previous studies have reported that aP2-Agt mice exhibit adipocyte hypertrophy
[157]. Because adipocyte hypertrophy is associated with a pro-inflammatory adipokine
secretory profile, increased MCP-1 levels in adipose tissue of transgenics could be due to
either a direct action of Ang II on adipocytes, or an indirect effect due to adipocyte
hypertrophy. To address this issue, we subjected 3T3-L1 murine adipocytes to a shortterm (24-hour) treatment of Ang II (10 nM). As shown in figure 15, Ang II increased the
secretion of MCP-1 and resistin from adipocytes. Because Ang II is known to activate the
nuclear factor kappa B (NF-kB) pathway, we treated the adipocytes with Ang II in the
presence of an NF-kB inhibitor (Bay 11-7082). As expected, Bay 11-7082 suppressed the
Ang II-induced increases in MCP-1 and resistin secretion from adipocytes. This indicates
that Ang II induces MCP-1 and resistin secretion from adipocytes in an NF-kB pathwaydependent manner. To further investigate the mechanism of Ang II-mediated stimulation
of the NF-kB pathway, we treated the adipocytes with Ang II in the presence of NADPH
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Figure 14. Adipose Agt overexpression induces inflammatory markers in adipose tissue
Male aP2-Agt wild-type (Wt) and transgenic (Tg) mice were fed a low-fat diet from
weaning until 24-weeks of age. Epididymal adipose tissue cytokine levels normalized to
total protein content are shown. Data are presented as mean ± SEM (n=5 per group). * p
< 0.05
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Figure 15. Ang II induces MCP-1 and resistin secretion from 3T3-L1 adipocytes
Differentiated 3T3-L1 adipocytes were treated with control (DMSO), Ang II (10nM),
Ang II plus NFkB inhibitor Bay 11-7082 (5μM), Ang II plus NADPH oxidase inhibitor
apocynin (200μM), Ang II plus AT2R antagonist P-186 (100nM) or TNF α (100pM) for
24 hours. Culture media MCP-1 (A) and resistin (B) levels are shown. Data are presented
as mean ± SEM (n=3 per each group). Different letters indicate a significant difference (p
< 0.05)
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oxidase inhibitor, apocynin. As shown in Figure 15, apocynin also completely prevented
the Ang II-induced increases in MCP-1 and resistin secretion. We have previously shown
that Ang II effects in 3T3-L1 adipocytes are mediated by AT2 [216]. To test whether
these changes were mediated via AT2, we treated the adipocytes with Ang II in the
presence of an AT2 antagonist. We found that this antagonist was able to partially prevent
the Ang II-induced MCP-1, but not resistin secretion.

Adipose angiotensinogen overexpression induces MGL expression
Proteomic studies of epididymal adipose tissue were used to identify novel
proteins induced by adipose angiotensinogen overexpression of adipose weight-matched
transgenic and Wt litermates, using 2DIGE. Several spots differentially expressed
between the Wt and transgenic mice were identified (Figure 16A and B), quantified
(Figure 6C), and proteins were identified by mass spectrometry. The detailed list of
proteins is given in Table 6. Transgenics exhibited higher expression of glycerol-3phosphate dehydrogenase, a major lipogenic enzyme and MGL, a lipolytic enzyme. The
differential expression of MGL was confirmed by western blotting as shown in Figure
16D and E. Proteins expressed at low levels in the transgenic mice include catalase, an
antioxidant enzyme.

Discussion
These studies provide the first evidence that adipose RAS components directly
link to insulin resistance. Male aP2-Agt mice develop glucose intolerance and systemic
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Figure 16. Adipose agt overexpression induces monoglyceride lipase in adipose tissue
Male aP2-Agt wild-type (Wt) and transgenic (Tg) mice were fed a low-fat diet from
weaning until 24-weeks of age. Epididymal adipose tissue proteomic studies were done
in adipose weight-matched mice. Differentially expressed spots between Wt and Tg are
shown (A and B). Spots were quantified (C), picked and identified using mass
spectrometry. Detailed list of proteins are given in Table 6. Monoglyceride lipase
expression between Wt and Tg was confirmed by western blot (D and E). Data are
expressed as mean ± SEM (n=4-5 per group). * p < 0.05
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Table 6. Proteins differentially expressed in adipose tissue in low-fat fed aP2-Agt mice
Protein Name

GI Accession No

Tg/Wt spot
volume ratio#

Tg higher Expression than Wt
Triosephosphate isomerase 1
Gpd1 protein (glycerol-3-phosphate dehydrogenase)
Vinculin
Isocitrate dehydrogenase 3 (NAD+) alpha
Eukaryotic translation initiation factor 5A, isoform CRA_a
Vitamin D-binding protein
Ehd2 protein
Medium-chain acyl-CoA dehydrogenase
Polymerase I and transcript release factor
Polymerase I and transcript release factor
Glutathione S-transferase, alpha 4
Fumarate hydratase 1
Mgll protein (monoglyceride lipase)
Anxa1 protein

6678413
13543176
31543942
18250284
148680528
193446
20072042
6680618
6679567
6679567
15215030
33859554
34786023
12805619

1.67
1.36
1.46
1.49
2.42
1.40
1.43
1.52
1.59
1.66
1.65
1.79
2.40
1.92

6753096
26665404
6754656
21618829
148702595
6680618
109571
51259985
37573976
47059037
56541070
6755202
21322147
31982861
38090288
160358829
157951741
6680121
475012
27227449
984636

0.17
0.25
0.20
0.26
0.35
0.35
0.35
0.21
0.41
0.35
0.39
0.50
0.50
0.20
0.29
0.64
0.64
0.68
0.68
0.25
0.34

Tg lower expression than Wt
Apolipoprotein A-I
Immunoglobulin gamma-1 heavy chain
Mannose binding lectin, serum (C)
Arhgdib protein
Galactokinase 1, isoform CRA_a
Medium-chain acyl-CoA dehydrogenase
Apolipoprotein A-I precursor - mouse
Dnm1l protein
Villin 2
Major urinary protein 2
Transthyretin
Proteasome beta 3 subunit
DOM1
Carbonic anhydrase 3
Similar to Sly protein
Hemopexin
Catalase
Glutathione S-transferase M2
G protein beta subuit like
Anti-human seminoprotein monoclonal antibody
65-kDa macrophage protein
#

Spots with a volume ratio of >30% and a consistent presence in replicate gels were

identified and analyzed by mass spectrometry. Tg – transgenics, Wt- wild-type
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insulin resistance, which is at least in part due to reduced skeletal muscle glucose uptake.
Moreover, the inflammatory profile of these transgenic mice is characterized by elevated
adipose MCP-1 levels. We further confirmed this in vitro, demonstrating that Ang II
increases MCP-1 secretion from murine adipocytes, in an NF-kB and NADPH oxidasedependent manner.

RAS overactivation, adiposity and insulin resistance
In agreement with previous reports, our aP2-Agt mice developed increased
adiposity even on a low-fat diet [157]. We have previously shown that Ang II increases
triglyceride content and lipogenic enzyme levels in murine adipocytes in vitro [216].
Similarly, we found that the expression of glycerol-3-phosphate dehydrogenase, a key
lipogenic enzyme, was expressed at higher levels in the adipose tissue of aP2-Agt
transgenics compared to non-transgenic controls. Interestingly, other models of systemic
RAS overactivation such as chronic Ang II infusion [159] and overexpression of human
AGT in liver [152], do not exhibit higher adiposity. The increased adiposity seen in aP2Agt mice strongly suggests that it is due to autocrine / paracrine actions of Ang II on
adipose tissue.
In addition to being moderately obese, male aP2-Agt mice are also glucose
intolerant and insulin resistant. Previous rodent models of RAS overexpression have
shown that chronic systemic RAS overactivation leads to insulin resistance. These
include the renin overexpressing hypertensive transgenic TG(mRen2)27 rat [191], and
chronic Ang II infusion models [202]. In this study we show that specific adipose Agt
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overexpression is sufficient to produce a level of glucose intolerance that is comparable
to Wt mice on a HF diet. An important finding of these studies is that HF feeding did not
further exacerbate glucose intolerance in aP2-Agt mice.

This suggests that similar

mechanisms operate in both instances. It is interesting that female aP2-Agt transgenics
remained glucose tolerant, which is likely due to the effects of sex hormones as reported
previously [383]; however further studies beyond the scope of this work, are warranted.
Since systemic RAS blockade improves insulin resistance and glucose tolerance in
numerous human and rodent studies [191, 374, 384], we tested whether blocking RAS
would improve metabolic alterations in the aP2-Agt mice. As expected, treatment with
ACE inhibitor captopril prevented the HF diet-induced glucose intolerance in both
transgenic and Wt mice. Previous studies in rodents with ACE knockout [175], renin
inhibition [191], renin knockout [173], AT1 blockade [375] or AT2 deletion [178] have all
shown improvements in insulin sensitivity and glucose tolerance. ACE2 overactivation
which lowers Ang II and increases Ang (1-7) has also been shown to promote insulin
sensitivity and glucose tolerance [206, 372].

Mechanisms of insulin resistance induced by RAS overactivation
Most models of obesity and insulin resistance exhibit both muscle and adipose
insulin resistance. Here, we found that while adipose tissue Rg was not impaired in the
aP2-Agt mice, these mice exhibited reduced skeletal muscle and heart Rg. This could at
least in part explain the whole body insulin resistance in transgenic mice. Several
potential factors might have caused skeletal muscle insulin resistance. We found that the
84

level of pro-inflammatory cytokine MCP-1 was almost two-fold higher in the adipose
tissue of transgenics compared to the non-transgenic control mice, while the level of antiinflammatory cytokine IL-10 was lower. Together, these findings indicate increased
inflammation in the adipose tissue of the aP2-Agt mice. Altered adipokine secretory
patterns due to adipose tissue inflammation could be a cause of skeletal muscle insulin
resistance [96]. It should however be noted that the plasma levels of several adipokines
(with the exception of leptin) was comparable between the Wt and transgenic mice. Thus,
a possible paracrine role of adipose tissue could be important in the reduced skeletal
muscle and heart Rg in the aP2-Agt mice. Indeed, previous studies have linked adipose
tissue distribution within skeletal muscle to insulin resistance [385]. Epicardial fat is also
known to produce proinflammatory cytokines, which is implicated in the post-operative
insulin resistance [386, 387]. In vitro studies have also shown that adipokine secretion
can impair insulin signaling of myocytes, suggesting cross-talk between the two tissues
[388].
The aP2-Agt transgenics also exhibited higher plasma Agt levels. Higher Agt and
Ang II levels were previously reported to induce skeletal muscle and vascular smooth
muscle insulin resistance by several mechanisms. First, the skeletal muscle blood flow
can be reduced due to the pressor effect of Ang II, resulting in lower glucose delivery.
Second, Ang II can also inhibit insulin signaling in muscle [389], resulting in reduced
translocation of Glut4, leading to reduced glucose transport. Increased Ang II levels are
also known to impair glucose-stimulated insulin release from the pancreatic islets [204].
Thus, the glucose intolerance in the aP2-Agt transgenics could be attributed to a
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combination of reduced skeletal muscle glucose uptake as well as reduced insulin
response in the pancreas, which could be exacerbated by their elevated blood pressure
[157]. Additionally, previous studies have also reported that Ang II increases hepatic
glucose production, which could also contribute to glucose intolerance [202]. We propose
that these metabolic alterations are mediated by Ang II, as evidenced by an improvement
of the glucose tolerance in the mice treated with ACE inhibitor captopril. While elevated
plasma Agt levels could contribute to the systemic insulin resistance in aP2-Agt mice as
outlined above, it is unlikely that it played a major role, because the difference in plasma
Agt levels between the two genotypes was modest compared to circulating concentrations
shown to be effective in causing insulin resistance in previous studies [202].

Ang II and adipose tissue inflammation
Adipose Agt overexpression increases markers of adipose tissue inflammation
(increased MCP-1 and decreased IL-10 in this study and increased IL-6 and IL1β in
previous reports [179]). aP2-Agt mice also exhibit higher adiposity and adipocyte
hypertrophy [157], and because the latter is associated with a pro-inflammatory adipokine
profile, the increased MCP-1 could be a result of adipocyte hypertrophy. However, we
showed that Ang II can also directly increase MCP-1 and resistin secretion from
adipocytes in vitro. Ang II’s ability to promote MCP-1 production in other cell types such
as preadipocytes [390] and pancreatic islets [391] has been reported previously. Further,
RAS blockade improved plasma MCP-1 and resistin levels in humans [392, 393].
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Ang II is also documented to simulate NADPH oxidase, leading to increased
production of reactive oxygen species, which can activate the NF-kB pathway and
production of proinflammatory cytokines in the skeletal muscle [196] and vascular
smooth muscle [394]. Thus, we investigated whether similar mechanisms operate in the
adipose tissue. We found that Ang II-induced MCP-1 and resistin secretion from
adipocytes was completely abolished by treatment with NADPH oxidase or NF-kB
inhibitors.
From our proteomic studies, we found that the expression of MGL, a lipolytic
enzyme, was two-fold higher in the epididymal adipose tissue of transgenics. MGL
cleaves 2-arachodonyl glycerol to form arachidonic acid (AA). Activation of MGL has
been shown to increase AA levels in vascular smooth muscle [395]. Elevated AA levels
induce secretion of pro-inflammatory cytokines [77] and PGE2 [382] in adipocytes in
vitro, thus MGL could be another mediator of Ang II-induced adipose inflammation. We
have previously shown that Ang II dose-dependently increases PGE2 secretion in murine
adipocytes in vitro [396]. However, direct effects of Ang II on MCP-1 via prostaglandins
remain to be tested.
Overall, the aP2-Agt transgenic mouse model is a valuable model for studies of
human obesity associated with insulin resistance and hypertension. This study provides
for the first time evidence of a causal link between adipose tissue Agt overproduction and
the generation of glucose intolerance and systemic insulin resistance. The mechanisms
are at least in part due to skeletal and cardiac muscle insulin resistance, resulting from
increased adipose tissue inflammation and systemic levels of Ang II.
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CHAPTER IV
ROLE OF ENERGY-RESTRICTED HIGH-FAT DIETS IN REVERSING
METABOLIC DERANGEMENTS OF OBESITY

Disclosure: The work described in this chapter in its entirety has been published in the
following reference with minor modifications in the numbering of tables and figures:
“Kalupahana NS, Voy BH, Saxton A and Moustaid-Moussa N. Energy-restricted high-fat
diets only partially improve markers of systemic and adipose tissue inflammation.
Obesity (Silver Spring) 2011 Feb;19(2):245-54”

Introduction
Obesity is associated with a number of co-morbidities including the metabolic
syndrome, which is characterized by atherogenic dyslipidemia, hypertension, insulin
resistance, and pro-inflammatory and pro-thrombotic states [397]. Individuals with the
metabolic syndrome have a greater risk of developing type II diabetes mellitus and
cardiovascular diseases [397]. Our previous work and that of others have shown that in
addition to serving as an energy store, adipose tissue also functions as an endocrine organ
by secreting adipokines such as leptin, adiponectin, resistin, tumor necrosis factor-α
(TNF-α), plasminogen activator inhibitor-1(PAI-1), monocyte chemotactic protein1(MCP-1) and angiotensin II [23, 382]. There is evidence that with the increasing
accumulation of fat inside adipocytes, the endocrine function of the adipose tissue
becomes dysregulated resulting in a change in adipokine secretory patterns, with a
predominant pro-inflammatory profile [90] . Further, there is evidence that with
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increasing accumulation of triglycerides, there is an onset of adipocyte death, remodeling
and inflammation [93, 381]. These changes of adipokine secretory patterns and release of
inflammatory mediators contribute to the development of insulin resistance, cardiovascular pathologies and the proinflammatory and prothrombotic state associated with
obesity.
Energy restriction is a main form of dietary intervention to treat obesity and
metabolic syndrome. It has been shown to not only reduce body weight and adipose
tissue mass, but also reverse the metabolic derangements resulting from diet-induced
obesity including an improvement of insulin sensitivity [398], and downregulate
inflammatory genes in the adipose tissue [273, 399]. The role of macronutrient
composition in a weight-loss diet, however, remains contentious [307]. Most health
agencies advocate a low-fat diet, while there are claims that low-carbohydrate, high-fat,
energy-restricted diets are more effective in bringing about weight loss [400]. Since the
increasing portion sizes of meals over the years have been linked to the obesity epidemic
[401], a reduction in portion sizes without changing the macronutrient composition seems
a logical alternative to reverse obesity. However, it not clear whether weight loss by these
high-fat, energy restricted diets is accompanied with improvements in the adipose tissue
inflammation and metabolic markers. Thus we tested the hypothesis that weight loss due
to a high-fat, energy restricted diet (analogous to a reduction in portion size without
changing food items) is accompanied with improvements in adipose tissue inflammation
and markers of the metabolic syndrome.
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Methods and Procedures
Animals and Diets
Male C57BL/6J mice aged 7-8 weeks were purchased from Jackson Laboratory
(Bar Harbor, ME). After a one-week period of acclimation, they were fed either a control
low-fat (LF, n=15) diet (10, 70 (35% from sucrose) and 20% of total energy from fat,
carbohydrates and proteins respectively; Research Diets: D12450B) or a high-fat (HF,
n=28) diet (45, 35 (17% from sucrose) and 20% of energy from fat, carbohydrates and
proteins respectively; Research Diets: D12451). Detailed diet composition can be found
at researchdiets.com. The mice were individually housed with standard 12 hour light /
dark cycles. After four months, half the mice on the high-fat diet were switched to an
energy-restricted (HFR) diet with the same macronutrient composition as the previous
high-fat diet. (Ad-libitum food intake of the HF group was measured daily and on the
next day 70% of that amount was then given to the HFR mice; thus HFR mice were fed
70% of calories taken by the HF group), while the other half continued on the ad-libitum
high-fat feeding. Mice were terminated two months later, using the CO2 inhalation
method, following an 8-hour food deprivation with water available. These protocols were
all approved by the Institutional Animal Care and Use Committee of the University of
Tennessee, Knoxville

Plasma glucose, insulin, triglycerides and non-esterified fatty acids measurements
Following sacrifice, blood was collected into tubes with EDTA, kept on ice for
10min, centrifuged at 10,000 g for 10minutes, supernatant collected and stored at -80oC
90

for subsequent analyses. Glucose and insulin concentrations were measured by glucose
oxidase and a commercially available enzyme immuno assay (EIA) kit (Crystal Chem
Inc., Downers Grove, IL) respectively. Homeostasis model assessment of insulin
resistance (HOMA-IR) was calculated as glucose concentration (mmol/l) * insulin
concentration (mU/l) / 22.5 [402]. A commercially available EIA kit was used to assay
the plasma total adiponectin level (Linco Research, Billerica, MA), while colorimetric
assays were used to measure plasma triglycerides and non-esterified fatty acids (Wako
chemicals USA inc., Richmond, VA). All assays were performed according to the
manufacturers’ protocols.

RNA isolation and microarray
Total RNA was isolated from gonadal (epididymal) adipose tissue using Trireagent (Sigma Inc., St.Louis, MO). Five µg of total RNA was used to setup first strand
cDNA synthesis reaction with an Affymetrix oligo (dT) primer and Superscript II reverse
transcriptase (First strand cDNA synthesis kit, Invitrogen). Second strand synthesis
reaction was setup by addition of E.coli DNA ligase, E.coli Pol I, and RNAse H to the
first strand. cRNA labeling, hybridization to, washing and scanning of the GeneChip
Mouse Genome 430 2.0 array were performed using standard protocols [403]. RNA
samples from each of 3 animals in each group were used for microarray analysis.
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Western blotting
Total proteins were isolated from gonadal (epididymal) adipose tissue by
homogenizing with modified RIPA buffer containing a cocktail of protease inhibitors.
Protein concentration was determined by the Bradford assay [404]. Twenty micrograms
of total protein was loaded into each lane and separated by electrophoresis in an 8-10%
polyacrylamide gel. Proteins were transferred to a nitrocellulose membrane in transfer
buffer, blocked overnight with 5% non-fat dry milk in tris-buffered-saline and 0.1%
tween, incubated with polyclonal antibodies against PAI-1(Santa Cruz biotechnology)
and tubulin (Millipore), incubated with secondary antibodies containing horse radish
peroxidase (HRP) and finally detected by chemiluminiscence.

Plasma and adipose tissue adipo / cytokine measurements
Plasma leptin and PAI-1, and cytokine content in the gonadal adipose tissue
homogenized in modified RIPA buffer were measured using a commercially available
microsphere based multiplexing system (Luminex xMAP–Millipore, Billerica, MA).
Adipose tissue cytokines were normalized to total protein content.

Liver triglycerides and oil-red-o staining
Livers were homogenized as described by Miao et al [405]. Briefly, they were
homogenized in saline and solubilized in 1% deoxycholate. Triglycerides were assayed
using a colorimetric method (Wako chemicals USA Inc.) and normalized to liver weight.

92

Frozen sections of livers were made, stained with oil red o and counterstained with DAPI
as described previously [406].

Quantitative real-time PCR
Total RNA (5μg) was reverse transcribed and quantitative real time PCR was
performed using the SYBR Green method with ABI 7300 Sequence Detection System.
Levels of RNA were normalized to those of a housekeeping gene, acidic ribosomal
phosphoprotein P0 (36b4). The primers were ordered from Sigma Genosys (Sigma Inc.,
St.Louis, MO) and the sequences are given in Table 7. Relative expression of RNA was
compared to the HF group using the delta-delta ct method [407].

Statistical Analysis
Body weight and other parameters were compared for between-group differences
by one way ANOVA using SPSS (ver15.0 SPSS Inc., Chicago, IL) software. If the F test
was significant, group means were compared using the Bonferroni post-hoc test for
multiple comparisons. Adipose cytokines and liver triglycerides were compared between
HF and HFR groups using the independent samples t-test, while RT-PCR data were
expressed relative to the HF group using the one-sample t-test to determine significance.
Microarray data were uploaded and stored in the UTMD (University of Tennessee
Microarray Database). UTMD is an implementation of the Stanford Microarray Database
(SMD) package. Data was analyzed using Significance Analysis of Microarrays (SAM –
ver 3.0) [408] and DAVID bioinformatics resources, 2008 [409]. Differentially expressed
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Table 7. Primer sequences used for quantitative real-time PCR
Gene
Symb
ol
Thbs1

Gene Name

Forward primer (5'-3')

Reverse primer (5’-3’)

Thrombospondin 1

Cd59a

CD59a antigen

Adpn

Adiponutrin

Scd2
Tlr1

Stearoyl-Coenzyme A
desaturase 2
Toll-like receptor 1

Fbln5

Fibulin 5

Fasn

Fatty acid synthase

36b4

Acidic ribosomal
phosphoprotein P0
Leptin

GGGGAGATAACGGTG
TGTTTG
GTTAGCCTCACATGC
TACCAC
TCACCTTCGTGTGCA
GTCTC
GCATTTGGGAGCCTT
GTACG
TGAGGGTCCTGATAA
TGTCCTAC
GCTTGTCGTGGGGAC
ATGAT
GGAGGTGGTGATAGC
CGGTAT
GAGGAATCAGATGAG
GATATGGGA
GAGACCCCTGTGTCG
GTTC
CACTGCCACAAGTTC
CCCC
TGTTCCTCTTAATCCT
GCCCA

CGGGGATCAGGTTGG
CATT
AGGAGAGCAAGTGCT
GTTCATA
CCTGGAGCCCGTCTC
TGAT
AGCCGTGCCTTGTAT
GTTCTG
AGAGGTCCAAATGCT
TGAGGC
TGGGGTAGTTGGAAG
CTGGTA
TGGGTAATCCATAGA
GCCCAG
AAGCAGGCTGACTTG
GTTGC
CTGCGTGTGTGAAAT
GTCATTG
TCTGTTCCATGAGGC
CATCAG
CCAACCTGCACAAGT
TCCCTT

Lep
Sfrp5
An

Secreted frizzled-related
sequence protein 5
Adiponectin
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genes were selected based on false discovery rate (FDR) less than 5% [410] for both
SAM and GO enrichment analyses. All data are expressed as mean ± SD.

Results
Animal characteristics and metabolic markers
As expected, mice lost 7.6 ± 3.4g of weight during the two-month period of
energy restriction (HFR). Their final body weights (33.6 ± 1.8g) were also significantly
lower than the mice on low-fat (LF) diet (39.1 ± 3.4g) (Figure 17A). The net energy
intake of the HFR group was 30% lower than the HF group and approximately 15% less
than that of the LF group (based on energy density of the diets and estimates of average
daily food intakes). Mice on LF and HFR groups had lower fat pad weights (Figure 17B)
than the high fat (HF) group (1.3 ± 0.5 and 1.0 ± 0.2 vs. 2.9 ± 0.5g). Plasma leptin levels
showed a pattern similar to the fat pad weights (Figure 17C) with the HF group having
the highest level (13.1 ± 8.3 ng/ml) followed by the LF (7.0 ± 3.4 ng/ml) and HFR (2.7 ±
1.4 ng/ml) groups. The fad pad and plasma leptin levels were not significantly different
between LF and HFR groups. The adiposity index (fat pad weight / “dead” weight)
showed a pattern similar to that of the fat pad weight, indicating a lower body fat content
in the HFR and LF mice.
The HFR group exhibited better insulin sensitivity than the other two groups as
indicated by their lower fasting plasma glucose when compared with the LF group (10.6
± 1.8 in HFR vs12.1 ± 1.5 mmol/l in LF), lower plasma insulin levels (40.5 ± 21 in HFR
vs. 161.3 ± 125.3 in HF and 180.3 ± 169.3 pmol/l in LF) and HOMA-IR when compared
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Figur

Figure 17. Body and fat pad weights of LF, HF and HFR groups
Weekly body weight (A) and gonadal fat pad weight (B), plasma leptin concentration (C)
and adiposity index (gonadal fat pad / body weight ratio D) at sacrifice of C57BL/6J mice
fed a high-fat (HF) low-fat (LF) or a high-fat reduced energy (HFR) diet (initially fed HF
diet and later restricted to a total energy intake to 70% of initial intake). Different letters
indicate a significant difference. (n=14-15 mice in each group)
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to the other two groups (Figure 18A, B and C). Plasma non-esterified fatty acid
concentration was lowest in the LF group (0.3 ± 0.1 mmol/l) followed by the HFR (0.56
± 0.15mmol/l) and HF (0.77 ± 0.09mmol/l) groups (Figure 18D and E). Plasma
triglycerides, in contrast, were significantly lower in the HFR group (43.7 ± 18.9mg/dl)
than both LF (63.7 ± 20.7mg/dl) and HF (62.0 ± 15.3mg/dl) groups. Surprisingly, plasma
total adiponectin level was significantly lower in the HFR (2.9 ± 0.4 µg/ml) group when
compared to the HF (3.7 ± 0.7 µg/ml) group (Figure 18F). Plasma PAI-1 levels, however,
were lower in the LF group (551 ± 89.9 pg/ml) than both HF (1557 ± 338 pg/ml) and
HFR (1600 ± 182 pg/ml) groups (Figure 18G).

Gonadal adipose tissue cytokines, gene expression and hepatic steatosis
Since the HFR group had persistent elevation of plasma PAI-1 and reduced
adiponectin levels, we next studied gonadal white adipose tissue (GWAT) cytokine levels
to examine whether similar changes were seen there. This showed that in contrast to
plasma levels, GWAT PAI-1 levels were comparable between LF and HFR groups,
which were significantly lower than that of the HF group (Figure 19A). Next we
compared levels of other cytokines between the HF and HFR groups to see whether
caloric restriction has improved levels of these as well. This showed that while the HFR
group had lower MCP-1 and IL-2 levels, the levels of GM-CSF, IFN-γ, IL-1β, IL-6 and
IL-10 were comparable between the HF and HFR groups (Figure 19B).

97

Figure 18. Plasma metabolic markers of LF, HF and HFR groups
Fasting plasma glucose (A), insulin (B), homeostasis model assessment of insulin
resistance HOMA-IR (C), non-esterified fatty acids (D), triglycerides (E), adiponectin (F)
and plasminogen activator inhibitor-1 (PAI-1) (G) concentrations at sacrifice of
C57BL/6J mice fed a high-fat (HF) low-fat (LF) or a high-fat reduced energy (HFR) diet
(initially fed HF diet and later restricted to a total energy intake to 70% of initial intake).
Different letters indicate a significant difference. (n=14-15 mice in each group).
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Figure 19. Gonadal adipose tissue inflammatory markers and hepatic lipid content in HF
and HFR groups. Gonadal adipose tissue plasminogen activator inhibitor-1 (PAI-1)
protein expression by western blot in C57BL/6J mice fed a high-fat (HF), low-fat (LF) or
a high-fat reduced energy (HFR) diet (A). Gonadal adipose tissue cytokine levels (B),
hepatic triglyceride content (C) and oil red O stained sections of liver (D) from HF and
HFR groups are shown. Different letters indicate a significant difference. (n=3, 7, 4-5 and
4 from each group for A, B, C and D respectively) * p<0.05
99

Since insulin resistance and lower plasma adiponectin levels are associated with hepatic
steatosis, and since the HFR group exhibited better insulin sensitivity despite lower
plasma adiponectin levels when compared to the HF group, we examined whether the
caloric restriction improved hepatic steatosis. Analysis of liver triglyceride content and
oil red o stained sections of the liver (Figure 19C and D) showed that the HFR group had
improved hepatic steatosis.
To analyze global gene expression changes in GWAT due to caloric restriction of
HF diet, we performed microarray analysis. When the HF and LF groups were compared,
36 genes were differentially expressed (FDR<5%). The LF group expressed lower levels
of genes involved in cytoskeleton remodeling (fibulin 5 and lysyl oxidase), Wnt signaling
pathway (secreted frizzled-related sequence protein 5 - Sfrp5) and lipid transport
(phospholipid transfer protein and lipocalin 7) and higher levels of genes involved in
lipogenesis (stearoly-coenzyme a desaturase 2 - Scd2) when compared to the HF group
(Table 8). Additionally, RT-PCR data showed that the LF group expressed lower levels
of several genes involved in inflammation (toll-like receptor-1, thrombospondin-1,
CD59a antigen) when compared to the HF group (Figure 20). When the HFR and HF
groups were compared, 1022 genes were differentially expressed (FDR <5%). The HFR
group expressed lower levels of genes involved in cell and focal adhesion and cytokinecytokine receptor interaction. These included Cd34 antigen, thrombospondin 1,
fibronectin 1 and integrin beta 1 (Table 9). The HFR group also expressed lower levels of
leptin and genes involved in cytoskeleton organization and biogenesis, Wnt signaling
pathway, endoplasmic reticulum (ER) associated degradation pathway and MAPK
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Table 8. Genes differentially expressed between low-fat (LF) and high-fat (HF) groups

Accession ID

Gene name

Gene
Symbol

Fold
Change
(log2)

FDR
(%)

LF LOWER EXPRESSION VS HF (31 GENES)

1416164_AT

Fibulin 5

Fbln5

-1.31

0.00

1423023_AT

Sfrp5

-2.54

0.00

1417963_AT

Secreted frizzled-related sequence
protein 5
Lysyl oxidase

Lox

-1.19

0.00

1417963_AT

Phospholipid transfer protein

Pltp

-1.69

0.00

1417109_AT

Lipocalin 7

Lcn7

-1.21

0.00

Camkk2

1.16

2.93

Ppp2r5b

1.20

0.00

Sorl1

1.52

0.00

1415822_AT

Calcium/calmodulin-dependent
protein kinase kinase 2, beta
Protein phosphatase 2, regulatory
subunit b (b56), beta isoform
Sortilin-Related Receptor, Ldlr
Class A Repeats-Containing
Stearoyl-coenzyme a desaturase 2

Scd2

1.72

0.00

1452132_AT

Riken cdna 0610030g03 gene

G03rik

1.18

0.00

LF HIGHER EXPRESSION VS. HF (5 GENES)
1424474_A_AT
1426811_AT
1426258_AT
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Figure 20. Gonadal adipose tissue gene expression in HF, LF and HFR groups
Gonadal adipose tissue gene expression by reverse transcriptase quantitative PCR in
C57BL/6J mice fed a high-fat (HF), low-fat (LF) or a high-fat reduced energy (HFR)
diet. * p<0.001 vs HF, ** p<0.05 vs HF, # p<0.05 vs LF (n=3 RNA samples from 3 mice
in each group)
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Table 9. Genes differentially expressed between high-fat reduced-energy (HFR) and
high-fat (HF) groups
Gene
Symbol

Fold
Change
(log2)

FDR
(%)

Cell adhesion molecules
1416072_AT
Cd34 antigen
1422445_AT
Integrin alpha 6
1426918_AT
Integrin beta 1

Cd34
ITga6
ITgb1

-0.84
-0.77
-0.79

4.30
4.68
4.30

Focal adhesion
1421811_AT
1418711_AT
1426642_AT

Thrombospondin 1
Platelet-derived growth factor, alpha
Fibronectin 1

Thbs1
Pdgfa
Fn1

-3.33
-0.62
-2.21

1.09
4.52
0.00

Cytokine-cytokine receptor interaction
1451462_A_AT Interferon (alpha and beta) receptor 2
1422582_AT
Leptin
1417936_AT
Chemokine (c-c motif) ligand 9

Ifnar2
Lep
Ccl9

-0.89
-2.30
-2.77

4.52
0.00
1.09

Cytoskeleton organization and biogenesis
1456292_A_AT Vimentin
1423626_AT
Dystonin
1444089_AT
Spectrin beta 2

Vim
Dst
Spnb2

-0.67
-0.88
-1.41

4.30
4.30
4.30

Wnt signaling pathway
1448201_AT
Secreted frizzled-related sequence protein 2
1436075_AT
secreted frizzled-related sequence protein 5
1436791_AT
Wingless-related mmtv integration site 5a

Sfrp2
Sfrp5
Wnt5a

-1.51
-2.39
-1.02

4.30
0
4.30

Canx
Skp1a
Edem1

-0.77
-0.52
-0.73

4.30
4.75
4.30

Mapkapk2
Edfr
Ikbkg

-0.39
-0.44
-0.51

4.52
4.75
4.75

Accession ID
Gene name
HFR LOWER EXPRESSION VS. HF (698 GENES)

ER associated degradation pathway
1422845_AT
Calnexin
1423149_AT
S-phase kinase-associated protein 1a
1451218_AT
ER degradation enhancer, mannosidase alphalike 1
MAPK signaling pathway
1426648_AT
Map kinase-activated protein kinase 2
1460420_A_AT Epidermal growth factor receptor
1435646_AT
inhibitor of kappab kinase gamma
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Table 9. Contd.

Accession ID
Gene name
HFR HIGHER EXPRESSION VS. HF (324 GENES)

Gene
Symbol

Fold
Change
(log2)

FDR
(%)

Rps6
Eif4b

1.01
0.92

4.11
4.11

Eef2

0.73
0.63

3.52
4.75

0.32

3.52

mTOR signaling pathway
1455981_AT
1426380_AT

Ribosomal protein s6
Eukaryotic translation initiation factor 4b

Protein synthesis
1424736_AT
Eukaryotic translation elongation factor 2
Eukaryotic translation elongation factor 1
1439439_X_AT delta
1450934_AT
Eukaryotic translation initiation factor 4a2
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Eef1d
Eif4a2

Table 10. Genes differentially expressed between low-fat (LF) and high-fat reduced
energy (HFR) diets

Accesion ID

Gene name

Gene
Symbol

Fold
Change
(log2)

FDR
(%)

Scd2
Dgat2
Sc5d

2.97
1.08
1.19

0.00
2.16
2.16

Cyp51
Fdps
Adpn
Hmgcs1

2.58
1.91
1.92
1.28

1.17
1.99
0.00
2.16

Irs3
Pfkp
Prkar2a

2.03
1.03
1.57

3.38
4.21
0.65

Rps6
Eif4b
Rpl6

-0.86
-0.97
-0.59

4.49
4.49
4.96

Cd52
Ndrg1
B2m
Psmb8

-2.09
-1.45
-2.72
-1.42

4.49
0.00
1.31
0.00

Thy1
Tlr1
H2-m3
Cosl
Psmb9

-1.53
-2.97
-1.26
-1.77
-1.54

2.04
2.52
3.70
2.04
2.52

LF HIGHER EXPRESSION VS. HFR (249 GENES)
Lipid biosynthesis
1415822_AT
Stearoyl-coenzyme a desaturase 2
1422678_AT
Diacylglycerol o-acyltransferase 2
1451457_AT
Sterol-c5-desaturase (fungal erg3, delta5-desaturase) homolog (s. Cerevisae)
1450646_AT
Cytochrome p450, 51
1423418_AT
Farnesyl diphosphate synthetase
1420655_AT
Adiponutrin
1433443_A_AT 3-hydroxy-3-methylglutaryl-coenzyme a
synthase 1
Glucose metabolism
1437672_AT
Insulin receptor substrate 3
1416069_AT
Phosphofructokinase, platelet
1452915_AT
Protein kinase, camp dependent
regulatory, type ii alpha
LF LOWER EXPRESSION VS. HFR (563 GENES)
Protein synthesis
1416141_A_AT Ribosomal protein s6
1426378_AT
Eukaryotic translation initiation factor 4b
1416546_A_AT Ribosomal protein l6
Immune system process
1460218_AT
Cd52 antigen
1456174_X_AT N-myc downstream regulated gene 1
1427511_AT
Beta-2 microglobulin
1422962_A_AT Proteosome (prosome, macropain)
subunit, beta type 8 (large
multifunctional protease 7)
1423135_AT
Thymus cell antigen 1, theta
1449049_AT
Toll-like receptor 1
1421358_AT
Histocompatibility 2, m region locus 3
1419212_AT
Icos ligand
1450696_AT
Proteosome (prosome, macropain)
subunit, beta type 9 (large
multifunctional protease 2)
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pathway. Conversely, The HFR group expressed higher levels of genes involved in the
mTOR pathway as well as overall protein synthesis, including ribosomal protein S6. In
the final comparison between LF and HFR groups, 812 genes were differentially
expressed (FDR < 5%). The LF group expressed higher levels of genes involved in lipid
biosynthesis when compared to the HFR group, including Scd2, HMG-CoA synthase 1
and adiponutrin (Table 11). The LF group also expressed higher levels of insulin receptor
substrate-3 (Irs-3) and phosphofructokinase. In contrast, the LF group expressed lower
levels of genes mediating immune response process and protein synthesis when
compared to the HFR group. These included toll like receptor-1 and thymus cell antigen
1 theta. Both the LF and HFR groups expressed lower levels of genes involved in cell
adhesion when compared to the HF group. Selected microarray results were validated by
reverse transcriptase quantitative PCR (Figure 20). These data demonstrate an excellent
correlation between changes in gene expression assessed by microarray and the real time
PCR validation.

Discussion
In this study we tested the hypothesis that weight loss due to an energy restricted
high-fat diet (analogous to a reduction in portion sizes) is accompanied by improvements
in adipose inflammatory profiles and markers of the metabolic syndrome. While several
previous studies have reported metabolic and adipose tissue gene expression changes due
to energy restriction [271, 273, 411], to our knowledge this is the first study to
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comprehensively investigate the long-term effects of a reduced energy high-fat diet on
metabolic markers, adipokine secretion and adipose tissue gene expression in mice.
Although the HF diet increased adiposity compared to the LF diet in our study,
there were no significant differences in fasting plasma glucose and insulin, measured
after 8h of food deprivation. However, data from our lab (unpublished) and others [412]
indicate that this 45% fat diet, as compared to the same LF diet causes insulin
insensitivity as evidenced by higher AUC during a GTT test, and higher gonadal adipose
tissue inflammation. The impaired glucose homeostasis is milder than that caused by
commonly used 60% HF diets, which causes extreme changes in adipose inflammation
and remodeling [381]. Thus, we believe that 45% HF diets are more appropriate when
modeling human nutrition and obesity. Second, a prolonged starvation period of 8 hours
prior to the measurements likely contributed to the comparable levels of insulinemia and
glycemia in the HF and LF groups. Finally, it is also possible that the higher sucrose
content of the LF diet (35% of energy as sucrose in the LF diet vs. 17% energy from
sucrose in the HF diet) led to smaller differences in glycemia and insulinemia between
groups [413]. Most importantly, our study clearly demonstrated that the HFR group
exhibited lower fasting plasma glucose, insulin and HOMA-IR indicating better insulin
sensitivity than the other two groups.
The HFR group also exhibited improvements in hepatic steatosis. These changes
are more likely related to weight loss or the direct effect of energy restriction rather than
due the fat content of the diet, consistent with findings from a recent large clinical trial
involving post-menopausal women, which showed that weight loss, rather than LF intake
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was associated with a reduced incidence of type 2 diabetes [312]. Thus, these findings
further support that weight loss, rather than macronutrient composition of the diet is
important in improving insulin sensitivity and hepatic steatosis.
It is worth noting that the HFR group exhibited evidence of better insulin
sensitivity than HF despite lower plasma adiponectin levels. Previous studies on humans
and rodents have yielded inconsistent results regarding the impact of weight loss on
plasma adiponectin [253, 414-417]. Although our RT-PCR data shows a trend for lower
adiponectin mRNA expression in the adipose tissue of the HFR group, neither these PCR
data nor the microarray analyses reached statistical significance. Thus it is likely that the
decrease in plasma adiponectin is due to reduced fat mass rather than due to its reduced
production in the adipose tissue, as adiponectin is also expressed in fat cell
differentiation-dependent manner [418]. It is also possible that the lowering of plasma
adiponectin level is due to the high fat content in the diet; this is a significant finding
since plasma adiponectin levels are negatively correlated with cardiovascular risk.
When other adipokines are considered, consistent with previous studies, plasma
leptin level in the HFR mice reduced to about 20% to that of the HF mice [378]. A
surprising finding was that the plasma PAI-1 concentration was similar between the HFR
and HF groups, which were two-folds higher than the levels measured in the LF mice.
Since previous studies showing improvements in plasma PAI-1 levels following energy
restriction have used low-fat diets [262], this could indicate a role of fat content of the
diet in modulating plasma PAI-1 levels. Despite high circulating PAI-1 levels in HFR
mice, PAI-1 protein content in GWAT was reduced (Figure 19A). Thus the finding that
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plasma PAI-1 levels remained elevated in the HFR mice suggests that other sources of
PAI-1 such as vascular endothelium and platelets may be important in determining the
final plasma levels [419]. However, no studies have investigated the secretory patterns of
PAI-1 from these tissues in response to dietary fat content. Our data suggests that fat
content of the diet could be a factor which influences PAI-1 secretion from non-adipose
sources in normal weight individuals. .
Similar to improvements in GWAT PAI-1 levels, the HFR group also exhibited
lower levels of MCP-1 and IL-2 when compared to the HF group. However, levels of
several other pro-inflammatory (GM-CSF, IFN-γ, IL-1β and IL-6) and anti-inflammatory
(IL-10) cytokines were similar between the HF and HFR groups. Further, GWAT gene
expression by microarray analysis showed that the HFR group expressed lower levels of
genes involved in cell and focal adhesion, cytokine-cytokine receptor interaction, ER
associated degradation pathway, cytoskeleton organization and biogenesis, Wnt signaling
pathway and MAPK pathway, when compared to the HF group. It is now established that
the insulin resistance occurring in high-fat diet- induced obesity is accompanied with a
chronic low-grade inflammation of the adipose tissue. This inflammatory process is
characterized by CD11c+ macrophage infiltration and phenotypic switch, while recent
evidence shows that adaptive immune responses of the T helper 1 (Th1) type could also
be involved [93]. Lower levels of MCP-1, PAI-1, IL-2 and lower expression of genes
linked to inflammation in the HFR group could indicate a partial improvement in adipose
tissue inflammation by energy restriction.

109

The exact trigger of the adipose tissue inflammatory process in diet-induced
obesity is hitherto unknown. Some have suggested that adipose tissue ER stress is a
triggering event for subsequent inflammation and development of insulin resistance in
obesity [64], which is reversed by weight loss [420]. The onset of ER stress is indicated
by an increase in chaperon proteins followed by the unfolded protein response. In our
study, the expression of calnexin, a gene encoding a chaperone protein, as well as Edem1,
a mediator of ER stress were lower in the HFR group when compared to the HF group.
This could indicate a possible reversal of ER stress in the adipose tissue following energy
restriction.
Rodent studies have indicated that increasing adipose tissue mass without a
similar magnitude increase in supporting vasculature could lead to tissue hypoxia,
triggering the expression of inflammatory genes [62].

Similar findings have been

recently reported in humans where it was shown that subcutaneous adipose tissue oxygen
partial pressure negatively correlated with adiposity [421]. Thrombospondin-1 (Tsp1), a
known inhibitor of angiogenesis, was expressed 10 times higher in HF compared to the
HFR group. Tsp1 has been previously shown to be expressed in the WAT of both humans
and rodents [50, 422], correlating with both BMI and insulin resistance in humans [50].
Since thrombospondin-1 protein (TSP1) was shown to be secreted by adipocytes in vitro,
it has been categorized as an adipokine. It is possible that TSP1 could be implicated in
the suppression of angiogenesis leading to tissue hypoxia as described above. Recently,
it was shown that TSP1 impairs nitric oxide signaling, possibly implicating it in
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vasoconstriction [423]. Thus, TSP1 could be an important mediator of cardiovascular
complications in obesity and merits further investigation.
Another interesting finding in this study was that expression of several genes
involved in the Wnt signaling pathway were reduced in the HFR group when compared
to the HF group. Inhibition of the Wnt signaling pathway is associated with increased
adipogenesis resulting in an adipocyte phenotype [424]. In this study, the HFR group had
lower expression of Sfrp2 and Sfrp5, two inhibitors of canonical Wnt signaling, possibly
indicating an adipogenic scenario in the HF group. Recently it was reported that secreted
frizzled-related protein 5 (Sfrp5) deficient mice on a high-fat diet develop severe glucose
intolerance [425]. It is possible that Sfrp5 is a factor necessary for normal adipose tissue
expansion, and lower expression of this gene in the HFR group could be a response to the
rapid reduction in adiposity due to caloric restriction. Along with the finding that the
HFR group had lower expression of genes involved in cytoskeletal organization and
biogenesis could indicate a remodeling process of the adipose tissue in the HF diet fed
mice. This is in agreement with Strissel et al., who showed that in C57BL/6J mice fed a
high fat diet, there is adipocyte death and remodeling occurring after 12 weeks [381].
It is interesting that despite the large difference in fat pad weights, there were
relatively few genes differentially expressed between the HF and LF groups. These
included a lower expression of inflammatory genes and a higher expression of lipogenic
genes in the LF group when compared to the HF group. The high sucrose content in the
LF diet likely contributed to the latter. In contrast, although there was no difference in the
fat pad weight between the HFR and LF groups, a large number of genes were
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differentially expressed between these two groups. Interestingly, several genes involved
in immune function had higher expression in the HFR group when compared to the LF
group. This shows that energy restriction only partially reverses the adipose inflammation
induced by high-fat feeding.
We identified a large number of genes expressed at higher levels in the HFR
group when compared to both HF and LF groups. A majority of these genes were
involved in protein synthesis and the mTOR pathway. Several previous researchers have
reported changes in adipose tissue gene expression in response to energy restriction.
Higami et al. reported that there is decreased expression of genes linked to inflammation,
cytoskeleton, extracellular matrix or cytoskeleton [273] and increased expression of
genes associated with mitochondrial energy metabolism and macronutrient metabolism in
the adipose tissue of mice subjected to caloric restriction [271]. Similar findings have
been reported for humans recently [277]. Linford et al. reported that energy restriction
prevented the age related downregulation of genes involved in mTOR pathway in the
adipose tissue of rats [411]. While data from gene expression of other tissues including
liver suggests that there is a downregulation of genes involved in synthetic activity with
energy restriction [426], our data and the above suggest that the response for energy
restriction could be tissue-specific.
In summary the current study provides important information regarding metabolic
and genomic differences in LF/high sucrose vs. HF/Low sucrose fed ad libitum or with
energy restriction; there are however a few limitations to our study. Since the weights of
the groups were not exactly matched, the changes in gene expression could be related in
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part to weight, and in part to the macronutrient composition of the diet. Further, it is well
established now that a remodeling process occurs in the adipose tissue of DIO mice after
12 weeks of 65% high fat feeding [381], and our studies lasted 24 weeks of 45% HF
feeding. Other limitations include limited cytokine and other analyses in adipose tissue
from LF-fed mice due to limited tissue. Finally, we used 3 samples from each group for
the microarray studies and although our stringent statistical analysis provides confidence
in our differential gene expression pattern, a higher number of replicates would have been
more desirable.
This study is consistent with previous findings that intake of a high-fat diet results
in obesity and is associated with upregulation of genes involved in inflammation and
thrombosis in the white adipose tissue. Our studies further demonstrate that energy
restriction: 1. despite the high fat content of the diet, reverses diet-induced obesity with
concomitant improvements in insulin sensitivity and hepatic steatosis; and 2. only
partially reverses the inflammation of the WAT, without improvement in some metabolic
markers involved in increasing cardiovascular risk. Our study supports the recommended
low fat intake for cardiovascular health and further emphasizes the importance of
considering sucrose content in the diet in the management of diabetes.
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CHAPTER V
MECHANISMS OF (n-3) POLYUNSATURATED FATTY ACID-MEDIATED
PREVENTION AND REVERSAL OF INSULIN RESISTANCE IN HIGH-FAT
DIET-INDUCED OBESITY

Disclosure: The work described in this chapter in its entirety has been published in the
following reference with minor modifications in numbering of tables and figures:
“Kalupahana NS, Claycombe K, Newman SJ, Stewart T, Siriwardhana N, Matthan N,
Lichtenstein A and Moustaid-Moussa N. Eicosapentaenoic acid prevents and reverses
insulin resistance in high-fat diet-induced obese mice via modulation of adipose tissue
inflammation.

Journal of Nutrition, 2010 Nov; 140(11):1915-22”

Introduction
Obesity is a major health problem in the United States with two-thirds of the adult
population being either overweight or obese [427]. It is causally linked to the metabolic
syndrome, which is characterized by insulin resistance, atherogenic dyslipidemia and
hypertension and also associated with a pro-inflammatory and a pro-thrombotic state.
Individuals with the metabolic syndrome have a higher risk of developing type 2 diabetes
and cardiovascular diseases [397]. In recent years, evidence has linked these metabolic
disorders, in part, to adipose tissue endocrine function. Indeed, adipose tissue secretes
numerous bioactive peptides collectively known as adipokines, which play important
endocrine roles in the regulation of glucose homeostasis, blood pressure and appetite
[23]. Increased adiposity leads to a chronic low-grade inflammation in the adipose tissue
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resulting in increased production of pro-inflammatory cytokines such as monocyte
chemotactic protein-1 (MCP-1), interleukin-6 (IL-6), tumor necrosis factor-α,
plasminogen activator inhibitor-1 (PAI-1) [428] and angiotensin II [32] and decreased
production of anti-inflammatory adipokines such as adiponectin [428]. These
dysregulations of adipokine secretory patterns are identified as a link between obesity and
the metabolic syndrome.
While caloric restriction leading to weight loss is the main dietary intervention to
treat metabolic syndrome, other dietary interventions such as ones targeted at reducing
adipose tissue inflammation independent of weight-loss are yet to be explored in detail.
Long-chain (n-3) polyunsaturated fatty acids of marine origin, namely eicosapentaenoic
acid (EPA) and docosahexaenoic acid (DHA) have been shown to have antiinflammatory properties [317]. In vitro, these (n-3) fatty acids prevent the arachidonic
acid (AA)-induced increase in pro-inflammatory eicosanoids in fat cells [382] as well as
inhibit the nuclear factor-κB (NF-κB) pathway activation in immune and cancer cells
[429]. Since dietary intake of these fatty acids results in their enrichment in adipose tissue
[430], we hypothesized that these fatty acids would prevent (P) and reverse (R) the
metabolic derangements occurring in diet-induced obesity (DIO) via modulation of
adipose tissue inflammation. Several previous researchers have shown that EPA and
DHA prevent the development of insulin resistance in high-fat diet fed mice in an
adiponectin dependent manner [323, 324, 347, 357, 431-434]. The aim of this study was
to determine whether EPA can prevent and reverse the metabolic complications resulting
from high saturated-fat (HF) feeding and to determine underlying mechanisms. We
115

hypothesized that EPA protects against HF diet-induced adiposity, insulin resistance and
hepatic steatosis and that these effects are mediated in part by their anti-inflammatory
effects on adipose tissue, as indicated by decreased secretion of pro-inflammatory
adipokines and increased secretion of adiponectin.

Materials and Methods
Mice and diets: Male C57BL/6J mice aged 5-6 wk were purchased from the Jackson
Laboratory (Bar Harbor, ME). Following a 1 wk period of acclimation, they were fed a
low fat (LF) diet (10, 20 and 70% of energy from fat, proteins and carbohydrates
respectively), HF diet (45, 20 and 35% of energy from fat, proteins and carbohydrates
respectively) or a high saturated-fat EPA (HF-EPA-P) diet (36 g/kg EPA ethyl ester) for
11 wk. A fourth group was initially fed the HF diet for 6 wk followed by the high
saturated-fat EPA diet (HF-EPA-R) for 5 wk. All four groups had 9-10 mice each. Diets
were custom made by Research Diets (New Brunswick, NJ) and the detailed diet
compositions are given in Table 11. Mice were housed in individual cages with free
access to food and water, and subjected to 12 h light/ dark cycles. Their food intake was
measured daily as the difference between the amount of food provided and the amount of
food removed after accounting for any spillage. Food was stored at -20 0C and the mice
were given fresh food daily. Mice were maintained on diet groups for 11 wk and weighed
weekly.
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Table 11. Composition of the diets for the EPA study

Fat , % energy
Carbohydrate, % energy
Protein, % energy
Digestible Energy, kJ/g

LF
10
70
20
16.1

Lard
Soybean Oil
EPA, Ethyl Ester
Mineral Mix, S100261
DiCalcium Phosphate
Calcium Carbonate
Potassium Citrate, 1 H2O
Vitamin Mix, V100011
Choline Bitartrate
dl-α-toco heryl acetate

19
24
0
9
12
5
16
9
2
0.12

Saturated fats
14:0
16:0
18:0
Monounsaturated
ats
14:1
1 :1(n-9)
18:1(n-9)
Polyunsaturated fats
18:2(n-6)
18:3(n-3)
20:4(n-6)
20:5(n-3)

25.1
0.5
16.5
8.2
34.7
0.2
1.8
32.7
40.2
34.6
5.0
0.7
0.0

1

HF- EPA
HF
45
45
35
35
20
20
19.8
19.8
g/kg
171
207
29
29
36
0
12
12
15
15
6
6
19
19
12
12
2
2
0.15
0.15
% total fatty acids
30.0
36.3
0.7
0.8
18.7
22.6
10.6
12.9
37.6
45.3
0.4
0.5
2.9
3.5
34.3
41.3
32.4
18.5
13.5
14.9
1.8
1.9
1.3
1.6
16.1
0.0

Research Diets, Inc. (New Brunswick, NJ, USA); composition of mineral and
vitamin mix as described previously by DeFuria et al. [47]
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At the end of 11 wk, mice were feed-deprived for 4 h and killed using the CO2 inhalation
method. Blood was collected into tubes with EDTA, kept on ice for 10 min, centrifuged
at 3,000 Xg for 20 min, and plasma samples were collected and stored at -80 oC for
subsequent analyses. Epididymal (gonadal), inguinal, retroperitoneal and subscapular fat
pads were dissected out, snap frozen in liquid N2 and stored at -800C for subsequent
analyses. These protocols were all approved by the Institutional Animal Care and Use
Committee of the University of Tennessee, Knoxville.

Glucose tolerance test: This was performed at two time points (6 wk and 10 wk into the
dietary intervention) in the same set of mice. Following a 12 h period of feed-deprivation,
5 μL of tail blood was used to measure the blood glucose levels using the one touch
ultra® glucometer. Next, 2 g/kg body weight of 20% D-glucose was injected
intraperitoneally. Serial blood glucose measures were taken at 15, 30, 60 and 120 min
after the injection.

Plasma insulin and adipokine measurements: Total protein was isolated from gonadal
adipose tissue by homogenizing with modified radio-immunoprecipitation assay (RIPA)
buffer containing a cocktail of protease inhibitors. Protein concentration was determined
by the Bradford assay [404]. Commercially available ELISA kits were used to measure
plasma insulin (Crystal Chem Inc., Downers Grove, IL) and total adiponectin (Linco
Research, Billerica, MA) concentrations. Homeostasis model assessment of insulin
resistance (HOMA-IR) was calculated as glucose concentration (mmol/L) × insulin
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concentration (mU/L) / 22.5 [19]. PAI-1, MCP-1 and IL-6 levels were measured using a
commercially available microsphere based multiplexing system (Luminex xMAP).
Analyte values in the adipose protein extracts were normalized to total protein
concentration. All assays were performed according to the manufacturers’ protocols.

RBC fatty acid profile: RBC samples from 2-3 mice per group were pooled prior to
analysis. Lipids were extracted from RBC membranes [435] followed by saponification
and methylation [436]. The resultant fatty acid methyl esters were quantified using an
established gas chromatography method as previously described [437]. Peaks of interest
were identified by comparison with authentic fatty acid standards (Nu-Chek Prep, Inc.
Elysian, MN) and expressed as molar percentage (mol %) proportions of total fatty acids.

Liver triglycerides (TG): Liver TG was measured as described previously [23]. Briefly,
the livers were homogenized in saline and solubilized in 1% deoxycholate. TG
concentration was assayed using a colorimetric method (L-Type TG M kit, Wako
chemicals USA Inc.) and normalized to liver weight.

Cell culture experiments: Adipocytes were cultured as described previously [382].
Briefly, 3T3-L1 preadipocytes were cultured in 100 mm dishes in regular growth media
consisting of DMEM supplemented with 10% fetal bovine serum and 1%
penicillin/streptomycin (PS). At confluence, the cells were differentiated by the addition
of growth media supplemented with 250 nmol/L dexamethasone, 0.5 mmol/L Methyl
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Isobutyl Xanthine and 10 nmol/L insulin for 48 h after which regular media was added.
After 6-7 d, the media was replaced with serum-free media (DMEM, PS, and 1% fatty
acid-free bovine serum albumin - BSA). Treatment media (above plus 10 nmol/L insulin,
dimethyl sulfoxide and AA or EPA) was added and kept for 48 h. Final fatty acid
concentration in the incubation media was 150 µmol/L. Both fatty acids were conjugated
to BSA prior to treatment (fatty acids to BSA molar ratio: 3:1). All fatty acids were
purchased from Nu-Check Prep Inc. (Elysian, MN).

Proteomics: Protein extracts from AA or EPA treated cells were labeled with cyanine
(Cy) 3 or Cy 5 (green and red), respectively. Both samples were run on a 2 dimensional
difference gel electrophoresis (2D-DIGE; Applied Biomics, Hayward, CA). A complete
analysis of all differentially expressed proteins was obtained using Decyder software
from which quantitative data was derived. Spots with a volume ratio of >30% and a
consistent presence in replicate gels were identified, obtained using the spot picker robot,
and proteins within each spot were enzymatically digested and analyzed by mass
spectrometry. Proteins identified from this analysis were then uploaded into DAVID
Bioinformatics Resources [24], where the functional annotation chart was used to search
for significantly enriched gene ontology (GO) categories.

Liver Histology: Sections from the liver were fixed in 10% buffered formalin, routinely
processed, sectioned at 5 μm and stained with hematoxylin and eosin. Liver sections were
examined by a pathologist who was blinded to the various treatment groups. The pattern
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and degree of macrovesicular steatosis was noted and the latter was graded as none, mild,
moderate or severe (0-3) [438]. The presence of microvesicular hepatosis was also noted.

Statistical Analysis: Body weight and other variables were compared for between group
differences using one-way ANOVA. If the F test was significant, group means were
compared using post-hoc tests. If the Levene statistic was not significant, the Tukey’s
post-hoc test for multiple comparisons was employed, otherwise the Games-Howell posthoc test was used. For the glucose tolerance tests, area under the glucose curves was
calculated and compared between groups. Inter-group differences for the presence of
heapatic steatosis were compared using Pearson's chi-square test. The fold difference of
protein expression in replicate gels in proteomic studies was compared using the onesample t test. All analyses were performed using SPSS (ver16.0 SPSS Inc., Chicago, IL)
software. The level of significance for all tests was p<0.05, while for the GO enrichment
analysis a cut-off of false discovery rate of less than 5% was used. All data are expressed
as mean ± SEM.

Results
Mouse characteristics and metabolic markers
Fatty acid analysis of red blood cells showed enrichment with dietary EPA (Table
12). As expected, the HF group gained significantly more weight (p<0.001) and had a
significantly higher mean body weight (p<0.001) at the end of the 11 week study period
when compared to the LF group (Figure 21, Table 13). While the HF-EPA-P group had a
higher mean body weight at the end of the study compared to the LF group, this was
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Table 12. Fatty acid composition of RBC in C57BL/6J mice in the LF, HF, HF-EPA-P, or
HF-EPA-R groups 1
LF

HF-EPA-P
b

46.5 ± 0.2
0.04 ± 0.00

12:0

0.45 ± 0.02

14:0

0.46 ± 0.00

Saturated fatty acids
10:0

HF

a

49.4 ± 0.1
0.06 ± 0.01

b

47.1 ± 0.2
0.05 ± 0.00

0.42 ± 0.01

0.47 ± 0.04

0.44 ± 0.01

0.41 ± 0.03

<0.001
NS

0.39 ± 0.03

NS

0.42 ± 0.00

18:0

12.6 ± 0.21

20:0

0.44 ± 0.01

0.49 ± 0.04

0.38 ± 0.02

0.43 ± 0.07

NS

22:0

0.31 ± 0.01

0.30 ± 0.02

0.32 ± 0.02

0.33 ± 0.04

NS

24:0

0.44 ± 0.02

0.47 ± 0.02

0.40 ± 0.04

0.50 ± 0.04

NS

b

b

b

16:1(n-9)

18.8 ± 0.1

15.0 ± 0.1

0.01 ± 0.00
0.40 ± 0.02
a

0.29 ± 0.00
b

0.32 ± 0.03

15.5 ± 0.21

<0.001

b

0.27 ± 0.02

11.8 ± 0.08

11.1 ± 0.05

11.1 ± 0.36

11.5 ± 0.11

18:1(n-7)

3.3 ± 0.08a

1.7 ± 0.01c

2.0 ± 0.01b

1.7 ± 0.06c

20:1(n-9)

a

22:1(n-9)

0.13 ± 0.01

24:1(n-9)

0.53 ± 0.03
34.7 ± 0.1
6.8 ± 0.1b
0.13 ± 0.01

20:5(n-3)
22:5(n-3)
22:6(n-3)
(n-6) fatty acids
18:2(n-6)
18:3(n-6)
20:2(n-6)
20:3(n-6)

0.68 ± 0.08

bc

0.08 ± 0.01

ab

0.39 ± 0.06

bc

37.7 ± 0.3
6.8 ± 0.1b
0.13 ± 0.02

0.27 ± 0.01b

8.2 ± 0.06a

b

5.2 ± 0.04

a

4.1 ± 0.17

b

0.79 ± 0.01
5.6 ± 0.04

a

27.7 ± 0.1b
6.3 ± 0.18b
0.17 ± 0.03
0.41 ± 0.02
1.5 ± 0.02

a

16.8 ± 0.11

22:2(n-6)

0.19 ± 0.05

22:4(n-6)

b

1.7 ± 0.02

0.89 ± 0.01

a

0.60 ± 0.01

d

7.8 ± 0.01

b

0.06 ± 0.01
a

0.34 ± 0.01
0.05 ± 0.00

b

1

0.06 ± 0.01

0.020
NS

7.9 ± 0.22a

<0.001

b

4.9 ± 0.12

a

<0.001

4.3 ± 0.18

b

<0.001

18.3 ± 0.2c
8.3 ± 0.07a

<0.001
<0.001

a

0.14 ± 0.01

NS

0.65 ± 0.02

a

0.36 ± 0.01

b

1.36 ± 0.02

b

0.71 ± 0.03

c

17.0 ± 0.65

a

b

0.11 ± 0.04
c

0.002

b

0.26 ± 0.05b

0.17 ± 0.01

0.36 ± 0.00

0.44 ± 0.07

ab

30.8 ± 0.4a
9.1 ± 0.42a
b

<0.001
c

<0.001
<0.001
NS

5.5 ± 0.09

0.14 ± 0.02
b

NS

35.8 ± 0.1
17.3 ± 0.3a
0.12 ± 0.01

0.90 ± 0.05

17.8 ± 0.1c
8.6 ± 0.11a

0.008
<0.001

0.43 ± 0.03

a

35.6 ± 0.2
17.7 ± 0.2a
0.12 ± 0.02

20:4(n-6)

22:5(n-6)

0.09 ± 0.02

ab

0.40 ± 0.00

c

PUFA
(n-3) fatty acids
18:3(n-3)

0.83 ± 0.08

0.6 ± 0.02

NS
b

b

18:1(n-9)

ab

<0.001

0.02 ± 0.00
ab

1.3 ± 0.01

a

0.6 ± 0.05

<0.001

a

15.0 ± 0.1

0.02 ± 0.00
b

31.5 ± 0.15

a

16:1(n-7)

1.2 ± 0.11

0.5 ± 0.02

15.5 ± 0.06

a

15.2 ± 0.5

0.01 ± 0.00
a

29.5 ± 0.10

b

NS

b

Monounsaturated fatty
acids
14:1

16.0 ± 0.13

a

49.2 ± 0.2
0.05 ± 0.01

31.7 ± 0.14

a

31.3 ± 0.12

p value

a

a

16:0

a

HF-EPA-R

1.9 ± 0.08

a

<0.001
<0.001

0.08 ± 0.03

a

0.71 ± 0.06

8.4 ± 0.13

<0.001

NS

0.42 ± 0.01

c

<0.001

0.11 ± 0.01

b

<0.001

Results are mean ± SEM, n=3. Means in a row with superscripts without a common
letter differ, P < 0.05. NS- p>0.10
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Table 13. Mouse characteristics and metabolic markers in C57BL/6J mice in the LF, HF,
HF-EPA-P, or HF-EPA-R groups 1
Variable

LF

HF-EPA-P

HF

HF-EPA-R

p value

Dead weight, g

31.7 ± 1.0c

35.9 ± 0.9b

40.4 ± 1.2a

40.6 ± 1.1a

< 0.001

Total fat pad weight, g

3.3 ± 0.2c

4.6 ± 0.3b

6.0 ± 0.3a

6.4 ± 0.3a

<0.001

Gonadal fat pad
weight, g

1.3 ± 0.1c

1.9 ± 0.1b

2.2 ± 0.1ab

2.4 ± 0.1a

<0.001

Inguinal fat pad
weight, g

0.8 ± 0.1b

1.1 ± 0.1b

1.6 ± 0.1a

1.6 ± 0.1a

<0.001

Adiposity index, %

10.3 ± 0.5c

12.8 ± 0.5b

14.8 ± 0.4a

15.6 ± 0.5a

<0.001

Cumulative energy
intake, kJ/ 11 wk

3784 ± 57b

4765 ± 68a

4807 ± 89a

4834 ± 120a

< 0.001

Glucose AUC at 6 wk,
min.mmol/L

1772 ± 118b

1947 ± 142b

2376 ± 86a

-

0.001

Glucose AUC at 11
wk, min.mmol/L

2099 ± 120b

2253 ± 83b

3289 ± 186a

2943 ± 132a

< 0.001

Blood glucose,
mmol/L

10.2 ± 0.5b

9.7 ± 0.4b

12.2 ± 0.5a

10.1 ± 0.4b

0.002

Plasma insulin, pmol/L

69 ± 15b

39 ± 13b

330 ± 51a

149 ± 27b

< 0.001

HOMA-IR

4.5 ± 1.0b

2.4 ± 0.8b

25 ± 5.2a

9.8 ± 2.0b

< 0.001

ab

c

b

a

Plasma total
adiponectin, mg/L

27 ± 1.0

30 ± 0.8

Plasma PAI-1, ng/L

382 ± 53b

551 ± 52ab

632 ± 69a

550 ± 76ab

Plasma TG, mmol/L

0.43 ± 0.03ab

0.37 ± 0.02b

0.48 ± 0.03a

0.39 ± 0.03ab 0.04

222 ± 29b

215 ± 32b

400 ± 52a

260 ± 35b

0.005

MCP-1, ng/g
protein

18 ± 2.4b

22 ± 3.9b

130 ± 45a

72 ± 12ab

0.002

Liver TG,2 μmol/g

40 ± 4.4bc

33 ± 2.1c

82 ± 2.4a

54 ± 6.2b

<0.001

21 ± 0.7

31 ± 0.8

< 0.001
0.027

Gonadal adipose
cytokines
PAI-1, ng/g protein

1

Results are mean ± SEM, n = 9-10. Means in a row with superscripts without a common letter
differ, P < 0.05
2
n=4
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Figure 21. Effects of dietary fat content and EPA on weight gain
Change in body weight over time in C57BL/6J mice in the LF, HF, HF-EPA-P, or HFEPA-R groups is shown. Data are presented as the mean ± SEM, n= 9-10. Labeled means
at a time without a common letter differ, P < 0.05 (Representative differences in weight
gain are shown)
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significantly lower compared to the HF group (p<0.05). The HF-EPA-R group had a
mean body weight comparable to the HF group. The total energy intake during the study
period was comparable among the HF, HF-EPA-P and HF-EPA-R groups, while it was
significantly lower in the LF group (Table 13). The fat pad weights and adiposity index
(fat pad weight / body weight) showed a pattern similar to that of body weight, with the
LF group having significantly lower values compared to the other 3 groups, and the HFEPA-P group having significantly lower values than the HF and HF-EPA-R groups
(Table 13).
The HF group developed glucose intolerance as indicated by a higher area under
the glucose curve (AUC) when compared to the LF group both at 6 and 10 weeks of the
dietary intervention (Figure 22, Table 13). The HF-EPA-P group maintained glucose
tolerance at both time points as indicated by a similar AUC to that of the LF group
despite higher body and fat pad weights in HF-EPA-P compared to the LF group.
However, there was no significant difference between the AUC of the HF-EPA-R and
HF groups (Figure 22C and D), indicating that EPA did not reverse the glucose
intolerance caused by HF feeding. Further, the HF group also exhibited significantly
higher glycemia and insulinemia following feed-deprivation, compared to the LF group
(Table 13). In contrast, glycemia, insulinemia and HOMA-IR score in the HF-EPA-P and
HF-EPA-R groups were similar to that of the LF group (Table 13). These data suggest
that EPA prevented and reversed the insulin resistance caused by HF feeding.
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Figure 22. Effects of dietary fat content and EPA feeding on glucose tolerance
Change in blood glucose over time during the glucose tolerance test in C57BL/6J mice in
the LF, HF, HF-EPA-P, or HF-EPA-R groups after 6 wk (panel A) and 10 wk (panel B)
is shown. Data are presented as the mean ± SEM, n= 9-10 (20 in the HF group for A).
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Plasma adiponectin concentration showed a similar pattern, with lower levels in the HF
group compared to all the other three groups. Plasma PAI-1 concentration however, was
higher in the HF group when compared to the LF group, while there was no significant
difference in PAI-1 concentration between the HF-EPA-P and HF-EPA-R groups. Plasma
triglyceride concentration was significantly lower (p<0.05) in the HF-EPA-P group when
compared to the HF group, while the concentration in the LF and HF-EPA-R groups were
not significantly different from the other two groups (Table 13). Plasma non-esterified
fatty acid concentration was similar among all four groups (data not shown).
Since the development of insulin resistance in HF feeding is known to be at least
in part due to adipose tissue inflammation, next we assessed some markers of adipose
tissue inflammation. This confirmed that gonadal adipose tissue PAI-1 level was higher
in the HF group when compared to the other three groups (Table 13). Gonadal adipose
tissue MCP-1 level was highest in the HF group compared to the LF and HF-EPA-P
groups, and intermediate in the HF-EPA-R group (Table 13).
Since plasma adiponectin concentration and markers of adipose tissue
inflammation were comparable between the HF-fed EPA groups and the LF group, we
next examined this issue using adipocytes, 3T3-L1 cells, treated with AA and EPA.
Analysis of culture media from 3T3- L1 adipocytes indicated that AA-treated cells
secreted less adiponectin than either control or EPA-treated cells (Figure 23A). This AA
induced reduction in adiponectin secretion was prevented by co-treating with EPA. In
contrast, EPA-treated cells secreted lower IL-6 levels when compared to both control,
AA or AA+EPA treated adipocytes (Figure 23B).
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Figure 23. Effects of EPA or AA treatment on adipokine secretion
3T3-L1 adipocytes were treated with either EPA or AA. Culture media IL-6 (panel A)
and adiponectin (panel B) levels are shown. Data are presented as the mean ± SEM, n= 5.
Means without a common letter differ, p<0.05.
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Given that systemic insulin resistance is also associated with hepatic steatosis,
hematoxylin and eosin staining of liver was used to assess macrovesicular and
microvesicular steatosis (Figure 24 for representative stained sections). This showed a
significant difference among groups (44%, 11%, 70% and 44% of mice in the LF, HFEPA-P, HF and HF-EPA-R groups, respectively, exhibited moderate to severe
macrovesicular or microvesicular steatosis; p<0.001). Similarly, liver TG levels of the
HF-EPA groups (P and R) were comparable to that of the LF group, while it was
significantly lower than that of the HF group (Table 13). Both these findings suggest that
EPA prevented and reversed hepatic lipid accumulation.

Protein expression in EPA and AA-treated adipocytes
To gain further understanding of global metabolic changes elicited by EPA
compared to AA, we conducted proteomic studies on 3T3-L1 adipocytes treated with
either EPA or AA. This showed that several proteins were differentially expressed
between the two groups (Figure 25). Identification of these proteins revealed that EPA
treated cells expressed higher levels of enzymes involved in carbohydrate metabolism
including citrate synthase, malate deydrogenase 2 and aconitase 2 when compared to the
cells treated with AA (Table 14). The EPA treated cells also expressed higher levels of
proteins involved in fatty acid metabolism (fatty acid binding protein 5, pyruvate
carboxylase, acyl CoA dehydrogenase, propionyl CoA carboxylase and acyl CoA
thiesterase). Several other proteins involved in cellular metabolism including heat shock
protein 1 expression were higher in the EPA-treated cells.
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Figure 24. Effects of dietary fat content and EPA feeding on hepatic steatosis
Liver histology in C57BL/6J mice in the LF, HF, HF-EPA-P, or HF-EPA-R groups is
shown. Representative hematoxylin and eosin stained sections of the liver from the four
groups are shown.
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Figure 25. Proteomic studies in EPA or AA-treated adipocytes
Differential expression of proteins in EPA (panel A) or AA (panel B) treated 3T3-L1
adipocytes (panel C - overlay of 2D-DIGE) is shown. Spots were identified using
Decyder software (panel D).
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Table 14. Proteins expressed higher in EPA-treated compared to AA-treated adipocytes.
Protein Name

GI Accession
Number

EPA/AA
Spot
volume
ratio1

13385942
46849708
21313536

2.0
1.6
1.7

31982186
18079339

1.7
1.8

Lipid metabolic process
Pyruvate carboxylase
Fatty acid binding protein 5, epidermal
Acetyl-Coenzyme A dehydrogenase, medium chain
Propionyl Coenzyme A carboxylase, beta polypeptide
Mitochondrial acyl-coa thioesterase 1

32822907
6754450
6680618
33585846
40538846

2.0
1.7
1.4
1.5
1.5

Response to heat
Stress-70 protein (PBP74/CSA)
Heat shock protein 1 (chaperonin)

903309
31981679

1.8
1.9

31982407
6680618
33585846
40538846
9789985
23271115
15808988
46849708
6754450
31982186
21313536

1.4
1.4
1.5
1.5
1.5
1.5
1.5
1.6
1.7
1.7
1.7

8079339
903309
3237111
1981679
2822907
3385942
6680027
6679439

1.8
1.8
1.9
1.9
2.0
2.0
2.2
2.2

TCA Cycle
Citrate synthase
Succinate-Coenzyme A ligase, ADP-forming, beta subunit
Dihydrolipoamide S-succinyltransferase (E2 component
of 2-oxo-glutarate complex)
Malate dehydrogenase 2, NAD (mitochondrial)
Aconitase 2, mitochondrial

Cellular metabolic process
Eukaryotic translation initiation factor 4E
Acetyl-Coenzyme A dehydrogenase, medium chain
Propionyl Coenzyme A carboxylase, beta polypeptide
Mitochondrial acyl-coa thioesterase 1
Isovaleryl coenzyme A dehydrogenase
Aldehyde dehydrogenase family 6, subfamily A1
Williams-Beuren syndrome chromosome region 1Homolog
Succinate-Coenzyme A ligase, ADP-forming, beta subunit
Fatty acid binding protein 5, epidermal
Malate dehydrogenase 2, NAD (mitochondrial)
Dihydrolipoamide S-succinyltransferase (E2 component of
2-oxo-glutarate complex)
Aconitase 2, mitochondrial
Stress-70 protein (PBP74/CSA)
Eukaryotic translation elongation factor 1 gamma
Heat shock protein 1 (chaperonin)
Pyruvate carboxylase
Citrate synthase
Glutamate dehydrogenase 1
Peptidylprolyl isomerase A
1

Spots with a volume ratio of >30% and a consistent presence in replicate gels were
identified and analyzed by mass spectrometry
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Table 15. Proteins expressed lower in EPA-treated compared to AA-treated adipocytes.
Protein Name

GI Accession
Number

EPA/ AA Spot
Volume Ratio1

Cellular catabolic process
Ubiquitin-conjugating enzyme E2L 3
Glycerol-3-phosphate dehydrogenase 1 (soluble)
Aldehyde dehydrogenase 1 family, member L2

6678481
6753966
21961590

0.48
0.48
0.53

Carboxylic acid metabolic process
Asparaginyl-trna synthetase
Glycerol-3-phosphate dehydrogenase 1 (soluble)
Aldehyde dehydrogenase 1 family, member L2

29789191
6753966
21961590

0.67
0.48
0.53

Protein metabolic process
Tubulin, beta, 2
Ubiquitin-conjugating enzyme E2L 3
Aldehyde dehydrogenase 1 family, member L2
Asparaginyl-trna synthetase
Clathrin, heavy polypeptide (hc)
Cofilin 1, non-muscle

22165384
6678481
21961590
29789191
33438248
55777182

0.53
0.48
0.53
0.67
0.59
0.56

Cytoskeleton organization and biogenesis
Tubulin, beta, 2
Gamma-actin
Cofilin 1, non-muscle

22165384
809561
55777182

0.53
0.62
0.56

1

Spots with a volume ratio of >30% and a consistent presence in replicate gels were
identified and analyzed by mass spectrometry
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In contrast, the EPA-treated cells expressed lower levels glycerol-3-phosphate
dehydrogenase, a key enzyme in lipogenesis, when compared to the ones treated with AA
(Table 15).

Discussion
It has been previously demonstrated [439, 440] that HF diet-fed mice develop
higher adiposity, glucose intolerance and insulin resistance when compared to the LF
diet-fed mice and EPA or DHA supplementation prevents the high-fat diet-induced
increase in adiposity [321, 357, 441]. Our results now demonstrate that EPA not only
prevented, but also reversed, the development of insulin resistance in response to HF
feeding.

Effects of EPA on insulin resistance and adipose inflammation
The effects of EPA and DHA on preventing excess weight-gain and development
of insulin resistance associated with high-fat feeding are thought to be mediated by
adiponectin [347, 357]. It is not clear from data from previous studies whether the
maintenance of plasma adiponectin levels was secondary to reduced adiposity. Our study
showed that the HF-EPA-R group maintained normal levels of plasma adiponectin despite similar adiposity compared to the HF group, suggesting adiposity-independent
effects of EPA on adiponectin secretion. Since plasma glucose and insulin levels were
comparable between the LF and both HF-EPA groups, as were plasma adiponectin
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concentrations, we conclude that adiponectin is a major factor in the EPA-mediated
prevention and reversal of insulin resistance.
Obesity is characterized by a chronic lowgrade inflammation in the adipose tissue
[381]. Since adiponectin is exclusively secreted by adipose tissue and since the presence
of pro-inflammatory cytokines are known to inhibit its synthesis and release [442], next
we investigated whether EPA modulated adipose tissue inflammation induced by HF
feeding. We found that gonadal adipose tissue levels of MCP-1 and PAI-1, two markers
of adipose tissue inflammation, were 85% and 50% lower, respectively, in LF and EPA-P
groups, compared to the HF group. Although the HF-EPA-R group exhibited adiposity
similar to that of HF group, EPA prevented increased secretion of these cytokines.
Consistent with these findings, in vivo, EPA prevented the AA induced suppression of
adiponectin secretion from cultured 3T3-L1 adipocytes. EPA also reduced IL-6 secretion
and other pro-inflammatory cytokines from these cells (data not shown). This evidence
suggests that EPA prevented and reversed the high-fat diet induced adipose tissue
inflammation.
Systemic insulin resistance and adipose tissue inflammation is associated with
hepatic steatosis [443]. Similarly, we found that a higher proportion of the HF group had
microscopic evidence of hepatic steatosis compared to the LF group. In contrast, the HFEPA-P group had the lowest incidence of hepatic steatosis while the HF-EPA-R group
had a value similar to the LF group. Liver TG levels also were significantly lower in the
LF, HF-EPA-P and HF-EPA-R groups compared to the HF group. This suggests a
protective effect of EPA on the development of HF diet-induced hepatic steatosis. These
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data are consistent with previously reported hypolipidemic effects of EPA and DHA
[434, 444] and may be secondary to EPA-induced hepatic AMPK activation [434] and/or
higher systemic insulin sensitivity and reduced adipose tissue inflammation.
Obesity is characterized by a pro-thrombotic state associated with elevated PAI-1
concentrations. Plasma PAI-1 concentration was higher in the HF group when compared
to the LF group, and intermediate between the two in the HF-EPA P and R groups. Given
that gonadal adipose tissue PAI-1 levels were similar between the LF and the HF-EPA
groups, it is possible that the higher plasma PAI-1 concentration of the two HF-EPA
groups could be due to their higher adiposity. It is also possible that the duration of the
study was too short to affect plasma PAI-1 concentration.

Effect of EPA on weight-gain and adiposity
The HF-EPA-P had lower adiposity when compared to the HF group, despite a
similar energy intake. Evidence from previous studies in mouse models suggests that
EPA and DHA increase lipid oxidation in the white adipose tissue [348] and small
intestine [349], in vivo, in adipocytes [350] and myotubules [351], in vitro, and
suppresses hepatic lipogenesis [445]. Consistent with these observations, our proteomic
studies in 3T3-L1 adipocytes showed that several proteins involved in tricarboxylic acid
(TCA) cycle and fatty acid β-oxidation were expressed at a higher level in the EPAtreated cells when compared to AA-treated ones. The EPA-treated cells also expressed
lower levels of glycerol-3-phosphate dehydrogenase, a key lipogenic enzyme. Since EPA
is known to stimulate an activator of fatty acid oxidation, AMP-activated protein kinase
136

(AMPK) in adipocytes in vitro [353], it is plausible that AMPK mediates EPA effects.
Further, peroxisome proliferator-activated receptor gamma coactivator 1α, a transcription
co-factor involved in mitochondrial biogenesis, was shown to be induced in the white
adipose tissue of EPA/DHA supplemented mice [348]. Expression of citrate synthase, a
marker of mitochondrial content, was higher in our EPA-treated adipocytes. While
evidence from our study and others point towards EPA’s lipid oxidizing effects, it
remains to be seen whether this translates into increased energy expenditure, leading to
reduced weight-gain. This is especially important to elucidate, since a recent study has
shown that increased mitochondrial fatty acid oxidation does not necessarily lead to
increased energy expenditure [40]. It is interesting that the HF-EPA-R and HF groups had
comparable body weights. This could potentially indicate limited EPA effect on energy
metabolism in already overweight (HF fed) mice. A longer intervention period would be
necessary to distinguish between the effect of EPA on prevention and reversal of HF diet
induced excess weight gain.
In addition to the once mentioned above, several novel proteins were identified by
proteomic analysis on 3T3-L1 adipocytes treated with EPA or AA. Fatty acid binding
protein 5 (mal1), is a mediator of retinoic acid-induced peroxisome proliferationactivated receptor-δ dependant fatty acid oxidation in adipocytes [41]. However,
overexpression of this chaperone protein has been previously shown to be associated with
insulin resistance in rodents [42]. Pyruvate carboxylase, another protein expressed higher
in EPA-treated adipocytes, has been shown to be highly expressed in some rodent models
of obesity [43]. Thus, it is not clear whether these in vitro changes of EPA-induced
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protein expression will be replicated under in vivo conditions, and merits further
investigation.
In obese rodent animal models the data are relatively consistent regarding a
positive effect of EPA or DHA on insulin resistance [323, 324, 347, 431, 433]. This is not
the case in humans. Most clinical studies on the effects of these fatty acids on insulin
resistance have been carried out in Type-2 diabetic patients. In a recent meta-analysis of
23 randomized controlled trials, it was concluded that while EPA or DHA significantly
lowered plasma TG, there was no significant effect on glycemic control [446].
Differences between the findings in obese rodents and humans may be attributable to the
stage of the disorder, associations in humans have only been explored after, rather than
prior, to disease onset or the absolute dose used.
In the present study we used a diet containing 36 g/kg EPA, which is equivalent to
6.75% of energy intake in those mice, fed a 45% fat diet. In comparison, the intake of
EPA/DHA in the United States is about 0.1 to 0.2 g/day [319] and the current
recommendations vary from 1g/day [319] to 3.5g/day [447]. There are few additional
limitations in this study. First, we did not directly measure the energy expenditure of the
mice, hence, are unable to attribute the lower adiposity of the HF-EPA-P group to higher
energy expenditure with confidence. However, results from our proteomic and metabolic
studies are consistent with increased energy expenditure. Another limitation of the study
was that we did not measure high-molecular weight adiponectin, which is known to be a
better associated with insulin sensitivity. Also, the prolonged period of food deprivation
prior to the GTT could have adversely impacted the results. Finally, we did not use
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stringent statistical criteria for our proteomic studies and the proteins that were
differentially expressed need to be validated by other methods prior to confirming these
changes.
In conclusion, the findings of our current study indicate that EPA both prevented
and reversed the HF diet induced insulin resistance in mice. The mechanism appears to
be at least in part via modulation of the adipokine secretory pattern. The relationship of
EPA and insulin resistance in humans remains to be determined.
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CHAPTER VI
DISCUSSION
The goal of this dissertation research was to elucidate adipose tissue function in
metabolic syndrome using genetic and nutritional manipulations/approaches, with
specific emphasis on the roles of inflammation and Angiotensinogen. As a genetic
manipulation, we used mice overexpressing Agt in the adipose tissue to study the role of
adipose RAS overexpression in the pathogenesis of insulin resistance. This was further
dissected mechanistically using cultured adipocytes. Next we used energy-restricted highfat diets and high-fat diets supplemented with EPA as dietary manipulations to prevent
and reverse insulin resistance and metabolic derangements induced by high-fat feeding.
Each of these studies are discussed separately in the previous chapters.
Our studies demonstrate that primary changes occurring in adipose tissue, such as
adipose specific overexpression of Agt, can lead to excessive adiposity, adipose tissue
inflammation and insulin resistance. This supports the current view that adipose tissue
dysfunction in obesity is causally linked to the pathogenesis of insulin resistance and
metabolic syndrome [84]. Moreover, we showed that dietary manipulations can improve
adipose tissue inflammation and systemic insulin resistance in an adiposity-dependent
(caloric restriction) as well as independent (EPA) manner. We further characterized
mechanisms involved in these instances, to enhance our understanding of adipose tissue
dysfunction in obesity.
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Adipose tissue inflammation in obesity
A chronic low-grade inflammation occurring in adipose tissue is causally linked
to the pathogenesis of insulin resistance in obesity [84]. In agreement with previous
studies, we found that both mouse models of obesity we employed, i.e., aP2-Agt mice
and HF diet-induced obese mice, exhibited adipose tissue inflammation and insulin
resistance. Further, the improvements in insulin resistance following the dietary
interventions were also accompanied by improvements in markers of adipose tissue
inflammation. This highlights the importance of adipose tissue inflammation in the
development of systemic insulin resistance.
The pro-inflammatory cytokine MCP-1 was consistently expressed at higher
levels in adipose tissue of both mouse models of obesity. Moreover, both caloric
restriction and EPA suppressed MCP-1 expression. These animal studies are further
supported by in vitro studies showing that Ang II treatment increases MCP-1 secretion by
adipocytes. Therefore, MCP-1 appears to be a key mediator of adipose tissue
inflammation in obesity. Indeed, previous studies have shown that MCP-1 knockout mice
are protected from HF diet-induced insulin resistance, with mice having adipose specific
MCP-1 overexpression developing insulin resistance [87]. Taken together, this shows that
MCP-1 is required for obesity-induced insulin resistance.
Additionally, our in vitro data demonstrated that Ang II induces pro-inflammatory
cytokine secretion form adipocytes in an NF-kB-dependent manner. Unpublished data
from our lab also shows that EPA improves adipose tissue inflammation via inhibition of
the NF-kB pathway [448]. The importance of this pathway in production of
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proinflammatory cytokines from immune cells is well established [449]. Here we show
that this pathway is also important as a key mediator of adipocyte function. We also
showed that the Ang II induced pro-inflammatory cytokine production by adipocytes was
dependent upon NADPH oxidase. Activation of NADPH oxidase results in increased
production of reactive oxygen species, which likely activates the NF-kB pathway [450].
Therefore, increased oxidative stress also appears to be a trigger for the activation of NFkB pathway [451]. Taken together, this highlights NF-kB pathway as a potential target
for alleviation of adipose tissue inflammation and systemic insulin resistance in obesity.

Role of hepatic steatosis in obesity-related insulin resistance
Both dietary manipulations in our studies induced improvements in hepatic
steatosis. Some researchers suggest that intrahepatic fat content, rather than visceral fat
content, is causally linked to the development of insulin resistance in obesity [452].
However, in both our dietary manipulations, improvement in hepatic steatosis was
accompanied by improvements in adipose tissue inflammation. Further, in the EPA study,
in already obese mice, EPA improved insulin sensitivity and hepatic steatosis without
inducing changes in adiposity. Despite the lack of change in adiposity, these mice
exhibited marked improvements in adipose tissue inflammation. Taken together, this
suggests that improvements in adipose tissue function, rather than adiposity itself is
related to improved insulin sensitivity and hepatic steatosis. Moreover, our unpublished
studies also show that EPA-fed mice have smaller adipocytes compared to HF-fed ones,
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further suggesting that improved adipose tissue function is associated with adipose tissue
remodeling.
EPA

supplementation

also

protected

against

HF

diet-induced

hypoadiponectinemia. Given that adiponectin protects against hepatic steatosis, it could
be a common modulator of both hepatic steatosis and insulin sensitivity in these mice. In
a previous human study which showed that intrahepatic fat, rather than visceral fat
content, is important in insulin resistance, individuals with higher intrahepatic fat also
had lower plasma adiponectin levels [452]. Taken together, this highlights the important
role of plasma adiponectin as a key mediator of metabolic derangements in obesity.

Role of adipose RAS in insulin resistance
Individuals treated with RAS blockers are protected from the development of
type-2 diabetes [119]. Moreover, systemic and adipose RAS are overactivated in several
models of obesity (Table 2). However, the exact role of adipose RAS overactivation in
the development of insulin resistance was hitherto unknown. We showed that primary
overactivation of adipose RAS via overexpression of Agt leads to increased adiposity,
adipose tissue inflammation and systemic insulin resistance. Moreover, the glucose
intolerance in both wild-type and aP2-Agt mice improved following treatment with ACE
inhibitor captopril. This highlights the importance of adipose tissue RAS in the
pathogenesis of insulin resistance.
To further confirm whether adipose RAS is directly responsible for the
pathogenesis of insulin resistance, it would be important to generate and study mice with
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adipose-specific knockdown of Agt. Work in this direction is currently under way in our
research group. Along these lines, preliminary unpublished data from in vitro studies
from our lab shows that Agt silencing in cultured adipocytes significantly suppressed
secretion of proinflammatory cytokines by adipocytes.
A point of contention has been whether Agt is consistently overexpressed in
adipose tissue in obesity. While some human studies show a positive correlation between
BMI and adipose Agt expression, some show a negative or no correlation (Table 2).
Animal studies also show that adipose Agt expression is strain-dependent (Table 2).
Aside from acute hormonal and nutritional control, this points toward a genetic
variability in regulation of adipose Agt expression. Indeed, plasma Agt levels show a
high degree of heritability in some populations [453]. Polymorphisms of Agt gene are
also associated with plasma Agt levels [454]. Similarly Agt promoter variants are
associated with adipose Agt expression [455]. Further characterization of RAS
polymorphisms associated with adipose Agt expression would facilitate individualized
genotype-based treatments in the future.
One limitation of the aP2-Agt study was that we used the adipocyte protein 2
(aP2) promoter for the overexpression of Agt in adipose tissue. While aP2 is primarily
expressed in adipose tissue, evidence suggests that it is expressed in immune cells as well
[456]. This could potentially lead to overexpression of Agt by these cells, and given that
immune cells play a major role in adipose tissue inflammation and insulin resistance, this
could act as a potential confounder in our study. Adiponectin-driven expression of
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angiotensinogen or other proteins in adipose tissue would provide a better alternative to
dissect the role of specific adipose genes in metabolic disorders.

Role of energy-restricted high-fat diets in improving insulin resistance
Caloric restriction leading to weight-loss is the most common form of weight loss
interventions to prevent and treat obesity-associated metabolic derangements. While most
health agencies recommend a low-fat diet, reduced-energy high-fat diets are also claimed
to be effective in this regard. We found that weight loss induced by an energy-restricted
high-fat diet was accompanied by parallel improvements in insulin resistance in mice.
However this energy-restricted high-fat diet was only able to partially reverse adipose
tissue inflammation. Moreover, plasma non-esterified fatty acids, adiponectin and PAI-1
levels showed no improvement compared to low-fat diets. Thus, these results also
question the long term safety of these high-fat energy restricted diets, especially
regarding cardiovascular risk, and support the current recommendation of low-fat diets
for improvement of the metabolic profile.
Another finding of this study was that the insulin resistance, as measured by the
HOMA score was comparable between the high-fat and low-fat diet-fed groups. While
insulin resistance is a common feature of high-fat feeding, the development of insulin
resistance in the low-fat group was likely to be due to the high sugar content of that diet.
In subsequent studies, we used a low-fat diet with low sugar content, which maintained
the insulin sensitivity of mice on that diet. This highlights the importance of sugar
content in low-fat diets used in animal studies.
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Role of EPA in improving HF diet-induced insulin resistance
We showed that EPA is able to both prevent and reverse the HF diet-induced
insulin resistance in mice. Importantly, we found that EPA improved these parameters
independent of loss of adiposity in already obese mice. Hence, EPA was able to
dissociate increased adiposity from adipose tissue inflammation. This is an important
finding, because it shows potential for development of therapeutic strategies to alleviate
adipose tissue inflammation and insulin resistance without inducing weight loss.
We found that adiponectin as a key mediator of EPA-induced improvements in
insulin resistance. Adiponectin is an insulin sensitizer, which improves insulin signaling
in skeletal muscle via preventing serine phosphorylation of IRS-1 [457]. It also activates
AMPK and induces fatty acid oxidation in skeletal muscle [458]. In our study, high-fat
feeding reduced plasma adiponectin levels which was both prevented and reversed by
EPA in vivo. Mechanistically, using cultured adipocytes, we demonstrated that AA
reduced adiponectin secretion, while EPA restored it. These findings are consistent with
human studies showing that EPA increases plasma adiponectin levels. In addition to its
insulin-sensitizing effects, adiponectin exerts both anti-inflammatory and antiatherogenic actions [106]. Thus, increasing plasma adiponectin levels via EPA
supplementation is a promising approach to reduce the cardiovascular risk in obese
individuals, especially considering other concomitant anti-inflammatory effects of this
nutrient.
One limitation of this study was that the dose of EPA used was relatively higher,
preventing direct extrapolation of the results to humans (equivalent dose for a human
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consuming 2000 kcal/d on a 30% fat diet is 10g of EPA/day). Although the triglyceridelowering actions of EPA are seen at around 2-3g of EPA /day, it is likely that higher
doses of EPA are needed to improve insulin resistance in humans. The effect of EPA in
preventing the progression of insulin resistance and pre-diabetes to type-2 diabetes in
humans needs to be further examined.
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CHAPTER VII
CONCLUSIONS AND RECOMMENDATIONS
General conclusions
We successfully used genetic and nutritional manipulations to dissect the role of
adipose tissue dysfunction in the pathogenesis of metabolic syndrome. We showed that
primary changes occurring in adipose tissue, such as overexpression of pro-inflammatory
proteins, such as Agt, can lead to adipose tissue inflammation and systemic insulin
resistance. We also showed that nutritional interventions targeted at reducing adipose
tissue mass (caloric restriction) and adipose tissue inflammation (EPA) can both lead to
improvements in systemic insulin sensitivity. These findings are summarized below:

1. Adipose specific overexpression of Agt leads to increased adiposity, glucose
intolerance and systemic insulin resistance. This is at least in part due to Ang II
mediated NADPH oxidase and NF-kB-dependent increases in adipose tissue
inflammation.
2. Weight loss induced by an energy restricted high-fat diet is accompanied by
parallel improvements in insulin resistance and hepatic steatosis. However, this
diet only partially improves markers of adipose tissue inflammation and
negatively impacts plasma adiponectin levels and does not reverse HF dietinduced increases in plasma non-esterified fatty acids and PAI-1.
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3. EPA can both prevent and reverse high-fat diet-induced insulin resistance and
hepatic steatosis in mice. Mechanistically, this is at least in part via EPA-mediated
improvements in adipose tissue inflammation.

Implications and Recommendations
Based on the findings of our studies we would like to make the following
recommendations. First, our studies support the current recommendation of low-fat diets
for improvement of metabolic derangements associated with obesity. Our findings also
support the American Heart Association’s current recommendation for an increase in
dietary intake of omega-3 fatty acids of marine origin.
We discovered that adipose specific RAS overactivation can lead to systemic
insulin resistance. To confirm the role of adipose RAS in the pathogenesis of insulin
resistance in high-fat feeding, studies using adipose-specific Agt knockout are warranted.
Our studies showed that EPA can both prevent and reverse the insulin resistance
induced by high-fat diets. It is likely that EPA prevents the progression of metabolic
syndrome and prediabetes to type-2 diabetes in obese humans. This hypothesis remains to
be tested in humans using both tested doses as well as lower doses of EPA.
We uncovered mechanisms by which Ang II modulates adipocyte function.
Further, we showed mechanisms by which EPA modulates insulin resistance.
Identification of agents that modify these molecular targets could lead to development of
novel therapeutic strategies to prevent and treat metabolic derangements in obesity.
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